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Abstract 
Background and Aims: Preliminary evidence indicates that the gene expression profile of circulating 
white blood cells is significantly affected by the exposure to cardiovascular (CV) risk factors. However 
the few available studies have several limitations, including small sample size and narrow range of genes 
tested. The aim of the present thesis is to provide a review of the current literature on this relationship 
and the presentation of the results of a clinical research program aimed at investigating the gene 
expression profile at whole-genome level in peripheral blood mononuclear cells (PBMC) of healthy 
volunteers in presence of CV risk factors and associated biomarkers. 
Materials and Methods: In the clinical study, PBMC’s expression profile was evaluated using Agilent 
whole genome oligonucleotide mRNA microarrays in 167 apparently healthy young-adults, all 
volunteers in a CV risk assessment study. Enrolled subjects were free of diabetes, CV and inflammatory 
diseases, and did not take pharmacological medications. Data analysis was performed using methods 
developed to address differential expression for quantitative phenotypes and enrichment of gene sets in 
ranked lists of genes. 
Results. Differential expression profiles were identified in presence of cigarette smoking, high LDL-
cholesterol concentrations, increased biomakers associated with CV risk (like IL-6 and TNF-alpha) and 
in presence of increased carotid intima-media thickness (IMT), a surrogate marker of atherosclerosis. In 
all these conditions, gene expression profile was characterized by a pro-inflammatory signature. More in 
detail, cigarette smoking was characterized by an over-expression of groups of genes and molecular 
pathways involved in the innate immunity, whereas smoking was associated with the over-expression of 
genes involved in the cell-mediated immunitary response and high IMT was characterized by an over-
expression of genes of the mitochondrial respiratory chain. Interestingly, in subjects who smoked and 
had high LDL-c compared to low LDL-c non-smokers, the transcriptomic profile was characterized by 
the co-presence of the two bio-signatures and the enrichment of both innate and cell-mediated 
immunity. The gene expression profile associated with gender, age, and different proportions of 
leukocyte sub-populations are also presented as collateral results. 
Conclusions: In conclusion, in apparently healthy young adults, the presence of several CV risk factors 
such as cigarette smoking, high LDL-cholesterol and thickened IMT are associated with the over-
expression of genes related to the inflammatory response. However, different risk factors are 
characterized by different transcriptomic “signatures”. Presented data and supportive literature suggest 
that gene expression profile in PBMCs reflects the biological processes involved in the chronic sub-
clinical inflammation that is a key patho-physiological element of CV disease. 
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1 Background and rationale 
 
 
1.1 Introduction 
 
Atherosclerotic cardiovascular disease (CVD) is the primary cause of morbidity and mortality in the 
developed world [1,2] and in many countries of the so-called 2nd world, a group of nations in which 
economic status is improving above the threshold of poverty. CVD comprises several pathologies of 
the vessels wall, including acute events (such as myocardial infarction, other acute coronary syndromes, 
and stroke) and chronic disease (myocardial angina, peripheral artery disease / claudicatio, cerebro-
vascular insufficiency). The pathophysiological basis of CVD is atherosclerosis, whose basic lesion is 
the “atherosclerotic plaque”, also called “atheroma”. The atherosclerotic plaque results from the focal 
deposit of lipids, especially LDL-cholesterol, in the sub-endothelial space, within the vessel wall. 
Despite the chronic nature of the disease, CVD is often undiagnosed in its clinical stages, before the 
onset of symptoms or complications. The first clinical presentation of CVD in more than half of 
patients with coronary artery disease is either myocardial infarction or sudden death [3]. 
The early identification of subjects that are going to experience an acute CVD event has remained a 
challenge, despite decades of extensive research and that many risk factors for CVD have now been 
clearly established and are target of specific therapeutic interventions. 
Indeed, approximately 40% of deaths from CAD occur in patients with total cholesterol levels lower 
than average for the general population. These data are confirmed by observations coming from the 
Framingham population (the first longitudinal observational study on CVD risk factors in the general 
population) in which 35% of newly diagnosed CVD events occurred in subjects with total serum 
cholesterol lower than 200 mg/dL [4], a level for long time considered as optimal. 
This fact clearly indicates that identification of individuals at high risk for CVD development goes 
beyond identification of risk based solely on elevated cholesterol levels. Thus, over the past 10 years, 
the emphasis in CAD prevention has broadened from primary prevention based on single risk factors, 
such as hyperlipidemia, diabetes or hypertension, to the identification of higher-risk individuals on the 
basis of global risk assessment. Because many CVD events continue to occur in individuals considered 
at intermediate risk on the basis of current risk assessment, there is growing interest in the use of novel 
risk factors and other diagnostic techniques to detect levels of higher risk among this broad population. 
However, traditional risk factors and new risk factors, such as hs-CRP or homocysteine, are able to 
predict the development of cardiovascular disease in no more than 50% of cases. 
 
 
1.2 Critical appraisal of clinical approach to cardiovascular risk 
 
1.2.1   Definition of CVD risk factor 
A cardiovascular risk factor is a condition that is associated with an increased risk of developing 
cardiovascular disease. The association is statistical, and increases the probability of developing a certain 
type of cardiovascular event over a determined period of time. However the simple association between 
exposure and event is not enough to define a risk factor. 
A “candidate” cardiovascular risk factor must meet several criteria: 
1) The statistical association between the factor and cardiovascular disease must be strong. 
Generally, the presence of the factor should at least double the risk of disease. 
2) In addition, the association should be consistent. The risk factor should produce disease 
regardless of gender, age, or race, and the association should be present in all or most of the 
studies in which it has been evaluated. 
3) The association must make biological sense. A factor may appear to be related statistically to a 
disease, but unless such a relationship is biologically plausible, the statistical association may 
have little meaning. 
A positive answer to all these points defines the presence of a marker of risk: a factor that is 
significantly associated to the events and defines the presence of a higher probability of disease 
independently whether or not the factor is causally related to the disease. 
A fourth criterion is mandatory to define a risk factor: 
4) A treatment that favorably changes the risk factor should reduce the incidence of disease.  
The factor must make an independent contribution to increasing an individual’s risk of developing 
disease and its correction must improve outcome incidence. Therefore, a risk factor is not merely an 
odds indicator, but usually is a target for pharmacological treatment in prevention strategies. 
In fact, clinical risk assessment has two major goals: to identify persons who are at risk for accelerated 
atherogenesis and acute coronary syndrome development, and to define a set of goals for intervention. 
Identification of risk factors has both risk assessment and prevention purposes, since, at least so far, all 
the prevention strategies have been focusing on risk factors reduction. 
Longitudinal studies on cardiovascular diseases consistently consider some risk factors as crucial for the 
identification of reliable and significant risk function for cardiovascular disease: metabolic factors (i.e., 
total and HDL cholesterol, fasting blood glucose), biological factors (i.e., blood pressure), or others 
linked to life style (i.e., smoking habit), evaluated together with age and gender. 
Other factors, less frequently used in risk functions, have been considered important in the definition 
of cardiovascular risk: i.e., family history for premature cardiovascular events, body mass index, physical 
inactivity, genetic features. 
 
Table 1: Traditional and novel CVD risk factors 
Non-modifiable risk 
factors 
Classical risk factors Emerging risk factors 
• Age 
• Male gender 
• Family history of 
premature CAD 
• Hypertension 
• Smoking 
• Diabetes 
• LDL cholesterol 
• Overweight/obesity 
• Sedentary lifestyle 
• Atherogenic diet 
• Triglycerides 
• HDL cholesterol 
• Small LDL particles 
• HDL sub-fractions 
• Lipoprotein (a) 
• Apolipoproteins 
• Homocysteine 
• ADMA 
• IFG/IGT 
• Metabolic syndrome 
Subclinical markers of atherosclerosis Inflammatory markers 
• Ankle-brachial pressure index (ABI) 
• Tests for myocardial ischemia 
• Flow-mediated dilation (FMD) 
• Carotid intimal-media thickening (IMT) 
• Coronary calcium 
• High-sensitivity C-reactive protein (hs-CRP) 
• Fibrinogen 
• Serum amiid A (SAA) 
• Adhesion molecules 
• Cytokines 
 
 
1.2.2   Clinical effectiveness of assessment of and intervention on CVD risk 
factors 
Current guidelines for the management of individual risk factors are provided by the third Adult 
Treatment Panel report (ATP III) of the National Cholesterol Education Program (NCEP) (5), the 
seventh report of the Joint National Committee (JNC VII) of the National High Blood Pressure 
Education Program (6), and the American Diabetes Association (ADA) (7,8). All of these guidelines are 
currently endorsed or supported by the American Hearth Association (AHA) and the America College 
of Cardiology (ACC), two of the most important scientific societies implementing guidelines on 
cardiovascular diseases. 
All these guideline reports have a similar approach on cardiovascular risk that is a modified use of the 
global absolute risk concept: the principle is the adjustment of the intensity of risk factor management 
to the global risk of the patient. Risk stratification for a single patient starts from the single risk factor 
which the guideline is addressed to (i.e. plasma cholesterol concentration or blood pressure levels): the 
risk factor is measured and based on the registered value the patient is classified in a risk rank system. 
Lower risk usually requires only clinical follow-up and higher risk grades require immediate 
pharmacological intervention. Only in case of intermediate levels of the risk factor, where no clear 
strategy has been identify between non-pharmacological and pharmacological interventions, the use of 
a global risk approach is used to further stratify the patient into sub-groups with different prevention 
strategies. 
In ATP II and JNC VI (the latest version of NCEP and JNC guidelines before the current ones), 
overall risk was estimated by a simple system of risk assessment that employed counting of categorical 
risk factors. Treatment goals for LDL cholesterol were set according to the number of risk factors. This 
system represented a blending of the concepts of relative and absolute risk in an effort to effectively 
institute prevention and limiting pharmacological intervention only to high risk individuals. 
The use of categorical risk factors has undoubtedly the advantage of simplicity but may be lacking in 
some of the accuracy provided by graded risk factors. In fact, the summation of graded risk factors 
provides a great advantage over the addition of categorical risk factors and it was already being 
recommended in risk management guidelines developed by joint European societies in cardiovascular 
and related fields. Advocates of this approach contend that the increased accuracy provided by the 
grading of risk factors outweighs the increased complexity of the scoring procedures. 
However, the choice of avoiding the use of a total risk estimate based on summation of risk factors that 
have been graded according to severity was determined mostly on a political basis: the major 
intervention in NCEP recommendations has been lifestyle changes; LDL-lowering drugs were reserved 
for persons with categorical elevations of LDL cholesterol who were projected to be at highest risk. 
After release of ATP II, several major clinical trials reported results showing the efficacy and safety of 
LDL-lowering drugs for primary prevention. These reports opened the door to wider use of LDL-
lowering drugs. In addition, after ATP II there has been a growing view that a more quantitative 
assessment of short-term risk is required for the selection of persons who will benefit most from 
intensive risk-reduction intervention. 
The ATP III panel was faced the choice between these two approaches and once again the choice was 
to cope with the need to reconcile the previous method of counting risk factors with the developing 
field of integrated, “global” risk assessment. There were advantages and disadvantages to each 
approach: risk factor counting would have provided continuity with previous ATP guidelines; allowed 
for a history of detected risk factors to be included in risk assessment; included family history of 
premature CHD; and provided a focus on the individual risk factors, each of which requires clinical 
intervention. However, risk factor counting alone also has disadvantages: it does not provide a 
quantitative estimate of absolute risk in the short term; it does not allow for variability in risk factor 
level or intensity (i.e., it uses only categorical risk factors); and it may underestimate the progressive 
impact of advancing age on absolute risk in older persons. 
The final method chosen was an attempt to capitalize on the advantages of both approaches. Risk 
factor counting is retained for initial assessment, but Framingham risk scoring, updated for ATP III, is 
layered over risk factor counting to improve risk estimation for refining decisions about goals, intensity, 
and types of LDL-lowering therapy in persons with multiple risk factors. 
 
1.2.3   Limitations of the “risk-based” approach 
The early identification of subjects that are going to experience an acute CVD event has remained a 
challenge, despite decades of extensive research and that many risk factors for CVD have now been 
clearly established. In addition, many of these risk factors can be adequately modulated. 
By definition, a risk factor is a clinically relevant parameter that shows an independent association with 
the future development of the disease in the exposed subjects and whose pharmacological correction 
decreases the incidence of future events. 
High LDL-cholesterol concentrations and hypertensions are two of the best established CVD risk 
factors. Nonetheless, in the Framingham Heart Study, as many as one third of all coronary heart disease 
events occurred in individuals with total cholesterol <200 mg/dL [4]. Considering that the average U.S. 
cholesterol level is approximately 210 to 220 mg/dL, almost half of all cardiac events occur among 
individuals with below-average lipid levels. In addition, the distribution curves of total serum 
cholesterol concentrations for subjects that will develop an acute CVD event and subjects free of 
events at the end of the 26 year follow-up of the Framingham cohort greatly overlap and there is no 
single value that can discriminate the two groups. The same phenomenon can be observed for 
hypertension: the curve of subjects with CVD and without CVD are almost completely overlapping 
and the sensitivity and specificity of using systolic or diastolic blood pressure values to identify subjects 
at higher risk is extremely poor [9], as shown in the next figure. 
 
Figure 1: Predictive power of blood pressure for the presence of cardiovascular disease 
 
Footnote to figure. Panel A shows the prevalence distribution for systolic and diastolic blood pressure in “Affected” and 
“Unaffected patients”. Panel B shows the detection rate and the corresponding risk of false positives stratified by blood 
pressure tentiles. 
 
From a certain point of view, it is the same concept of risk factor and its connection to the progression 
of atherosclerosis that comes with several major limitations. First, the risk factors predicts the course of 
a process in a group of patients and not of an individual. Furthermore, a low level of a particular risk 
factor does not necessarily exclude the development of an event. As illustrated for the case of 
hypercholesterolemia, quite a number of patients with rather low cholesterol levels develop 
cardiovascular events. This is mainly explained by the fact that although patients with the highest 
cholesterol have the highest risk, patients with marginally elevated cholesterol comprise the largest 
proportion of the population and therefore of the patients suffering a cardiovascular event. 
This limit appears to be partially overcome by the use of composite weighted risk scores such as 
Framingham’s that start from a population-based assessment of event rate over time and model the 
relative weight of each risk factor combining them in one single equation model. 
Despite the accuracy of these scores in predicting CVD events appears to be greater than what 
provided by the assessment of a single risk factor, age and gender still explain most of the variability of 
these scores and therefore of their accuracy. 
So taken together, risk factor-based assessment of cardiovascular risk (and therefore risk factor-based 
treatment) is currently the best and most viable option for prevention at the level of the population and 
the single individual despite the fact that people are treated that do not need treatment, that people are 
not recognized as being at risk for cardiovascular disease, and that people are treated without 
adequately depressing the activity of the disease process. 
In fact, the problem is how to define who we should treat and how to verify whether the treatment 
adequately dampens the systemic disturbance that drives atherosclerosis. 
 
 
1.3 The role of biomarkers in preventive cardiovascular medicine 
 
1.3.1   From risk factor to biomarker 
Since it is clear that risk factors are not connected to disease states on a one-to-one basis, the search for 
systemic biomarkers of the atherosclerotic process has been progressively increasing over the last 
decade. The term “biomarker” has been defined in 2001 by the NIH Working Group as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” [10]. Applications of 
biomarkers as stated by the NIH Working Group include the use as a diagnostic tool for the 
identification of those patients with a disease or abnormal condition, the use as a tool for staging of 
disease or classification of the extent of disease, the use as an indicator of disease prognosis and the use 
for prediction and monitoring of clinical response to an intervention. As such, the concept of a 
biomarker greatly extends the use of risk factor in cardiovascular disease. With the use of a biomarker 
comes the application of surrogate end-points, that is a substitute for clinical endpoints [10]. From the 
description, it is clear that the application of a biomarker to diagnose and follow atherosclerotic disease 
is preferable to the use of a risk factor or the response of a risk factor to risk factor modulation.  
 
In this view, the lack of representation of the stage and activity of the atherosclerotic disease before 
clinical manifestations is at least in part due to the lack of biomarkers that accurately identify active 
atherosclerotic disease before complications occur. Inflammation has been implicated in all stages of 
CVD and is considered to contribute to the pathophysiological basis of atherogenesis [11,12,13]. 
Inflammation may therefore serve as a potential source for markers of the disease process itself. In 
large epidemiological studies, various serum markers of systemic inflammation such as hs-CRP, 
fibrinogen, and interleukin-6 (IL-6) have been shown to predict cardiovascular events and to correlate 
with response to therapy [14,15]. 
More specifically, hs-CRP appeared to be a good marker to predict the development of peripheral 
artery disease in initially healthy physicians [16]. The reduced rate of progression of atherosclerosis after 
statin treatment has also been described to be significantly related to the reduction in hs-CRP [17].  
Evaluations of hs-CRP have been performed in a variety of other conditions; this has led to an 
evaluation of markers of inflammation in cardiovascular disease by a Center of Disease Control and 
American Heart Association workgroup [ 18 ]. The report recommends the use of hs-CRP 
measurements as independent risk, however, identifies several issues that need further research. One of 
these is that further research is needed to assure optimal measurement of the presence, level, and type 
of inflammation in an individual patient. The workgroup also identified that the combination of 
inflammatory factors in the classification of cardiovascular disease risk was not well-explored.   
Although potentially useful in risk stratification, the current systemic markers of inflammation lack 
sufficient disease specificity to be used satisfactory as a screening tool in the diagnosis of CAD [19]. 
The inaccuracy of current markers may reflect the fact that they are neither derived primarily from the 
vascular wall nor produced primarily by cells involved in the vascular inflammatory process. 
Furthermore, they may signal inflammation in a number of different organs and tissues, which may or 
may not have direct implications for the vasculature. 
Recently, a number of studies have examined several other biomarkers on an individual basis as 
potential novel risk factors for CVD [20,21]. Although these studies demonstrate that some of these 
inflammatory markers (those known to be expressed in the diseased blood vessel) can predict the onset 
of clinically significant CVD, none of the markers provide clinically meaningful incremental value over 
traditional risk factors in predicting CVD complications. 
Taken together, these data point at an interesting weakness of the use of CRP (or any other single 
biomarker) as a proxy indicator for cardiovascular disease: shortcoming in reflecting a complex disease 
state in an individual. In other words, it is highly likely that, due to the heterogeneity of the disease 
phenotype in the population at risk, a single marker may not provide sufficient biological information 
for an accurate assessment of vascular damage in the coronary circulation. 
This shortcoming has been approached by multimarker scores in which a composite of biomarkers are 
measured in parallel to assess risk. There are several considerations attached to the use of the 
multimarker approach, such as the potential interdependence of the markers. Another issue is that the 
course of event that starts with the presence of a risk factor to the occurrence of a cardiovascular risk in 
pathophysiological terms is a continuously changing complex condition. This is nicely illustrated by the 
large number of biomarkers that have been described for the various stages of atherosclerosis, in 
particular increased arterial vulnerability. It may well be overly optimistic to try to find one, or a small 
set, of biomarkers that will form an adequate reflection of the entire disease process. In other words, the 
stage and activity of a very complex disease likely can not be captured in a single parameter or a small set of parameters 
and thus a complex state may need a complex representation.  
In addition, there are also statistical considerations that need to be put into the discussion. Even in 
presence of apparently independent risk factors or markers that serve as variables of a multi-variate 
model, part of the biological variability of the modeled phenomenon (in this case CVD occurrence) is 
shared among the independent variables. For this reason, each variable that enters the model after the 
first carries less and less information since part of its variability is already explained by the rest of the 
model. For this reason, one single parameter explain a certain quote of the outcome variability, whereas 
a few parameters account for significantly more variability explained but much less than the sum of 
they can explain singly. This is the case of the composite risk scores that show a better predictive power 
that a single risk factor, but this increase in accuracy is not tremendous. Adding one single or a few 
further parameters at this point does not change the overall accuracy of the model, almost 
independently from the predictive power of the parameter itself. This is what happens adding hs-CRP 
or a composite score of few biomarkers to the risk score. 
The concept is clearly illustrated in the following figure. 
 
Figure 2: Risk prediction as a function of the variables put into the model 
 
 
In this context, the only possibility to significantly improve risk prediction is to add hundreds or 
thousands of biomarkers to the model in order to overcome the issue of the co-information. 
The identification of tens or hundreds of biomarkers need a discovery search among thousands or tens 
of thousands. Currently only high-throughput –omic technologies can provide such a tremendous 
amount of data of a single biological phenomenon in parallel. 
 
1.3.2   Biomarker discovery from circulating cells 
Much of the focus in finding new biomarkers for atherosclerosis has been on circulating proteins and 
mediators related to the inflammatory response. Very little attention has focused on the cellular 
component of the blood, which is remarkable, at least in view of the role of the monocyte population 
and other cell types in the initiation and progression of atherosclerosis. Interestingly, all cells in the 
blood stream are subjected to the same stresses as the endothelial cell layer, and will translate these 
stresses into responses such as inflammation and oxidative excess.  
From this standpoint it is important to underline that white blood cells, especially monocytes and 
lymphocytes, are indeed exposed to several and variate stimuli known to be related to the 
atherosclerotic process (see figure below): these cells are known to re-circulate into the vessel wall and 
the atherosclerotic plaques, where they are exposed to the local pro-inflammatory mediators. In 
addition, circulating into the bloodstream, they are also exposed to systemic inflammatory mediators 
such as CRP and other acute phase proteins. Finally, these cells are also directly exposed to several 
cardiovascular risk factors that are present into the blood or condition the blood environment such as 
high cholesterol or blood glucose concentrations, or arterial hypertension. 
 
Figure 3: Circulating WBCs are exposed to local and systemic inflammation 
 
 
In addition, it must be noted that leukocytes are not only exposed to CVD risk factors and involved in 
the pathogenesis and progression of atherosclerosis, but also that these basically are inflammatory cells, 
programmed to respond in a pro- or anti-inflammatory way to any environmental stimulus to which 
they are sensitive. 
We propose that the presence of one or more risk factors, together with normal physiological stimuli, 
induce changes in leukocyte gene transcriptions with patho-physiological responses. It should also be 
remarked that obtaining circulating cells is very easy compared to any biopsy technique currently 
available and, in fact, all widely applied diagnostic tests are derived from blood.  
A large amount of data has been collected in circulating leukocytes to test in-vitro or in-vivo the 
relationship between single biomarkers and CVD traits. However, the analysis of single candidate 
biomarkers can be as much deceiving in circulating cells than it is for circulating biomarkers. 
We therefore focused our attention on the massive screening of thousands of biomarkers from 
circulating white blood cells in order to accurately represent their physiology and pahto-physiology. 
Among the different, available “omics” that can be used to represent cellular phenotype, transcriptomic 
and proteomic appear to be the most suitable to be applied in this context. Transcriptomic is the 
investigation at high-throughput level of the transcribed RNA with a quantitative estimation of the 
concentrations of all the known cellular transcripts. Proteomic is a molecule-discrimination technique 
that allows separating hundreds of molecules mixed in a biological matrix. Although the molecular 
complex that has the highest correlation with the cellular phenotype is the protein, the proteomic 
approach still has several technical limitations. First, the amount of proteic molecules (including 
peptides) is enormous and therefore the proteomic assay should be preceded by purification steps to 
exclude all the proteins outside of a narrow molecular weight range. Therefore it is usually not the 
entire proteome to be tested but just a part of it. In addition, once separated the molecules and 
identified spot that are differentially represented between different groups, there is no automatic 
information describing which proteins are represented by the identified spots. Therefore a subsequent 
effort should be put in characterizing the molecules and their function. Finally, we are very far form 
having a comprehensive representation of the proteome. 
Instead, high-throughput gene expression analysis is currently essentially based upon the use of 
synthetic probes of already known genes or sequences. After the completion of the genome project, the 
almost complete totality of genes has been identified and a large quote of them has also been classified 
in functional ontology groups. Therefore, at the end of a gene expression analysis, it is clear which 
genes or transcripts are up- or down-regulated and what is the inter-relation among them. Since the 
totality of the known genes (and therefore the almost totality of the existing human genes) can be 
tested in parallel, gene expression provide a comprehensive holographic representation of the cellular 
phenotype. In presence of chronic exposure to environmental stimuli (like in the case of CVD risk 
factors) gene expression is significantly affected and reflects the long-term changes induced on the 
cellular metabolism. 
The rational for using high-throughput techniques (and especially gene expression profiling) is further 
explained in details in the next chapter. 
 
1.4 Rationale and use for high-throughput technologies for 
biomarker discovery 
 
1.4.1   The concept of phenotype from a cellular standpoint 
A phenotype can be generically defined as “The observable physical or biochemical characteristics of an 
organism, as determined by both genetic makeup and environmental influences” [American Heritage 
Dictionary; Houghton Mifflin Company, USA]. From biological or medical perspective, the phenotype 
of an individual organism is either its total physical appearance, constitution, and macroscopic clinical 
state or a specific manifestation of a trait (such as size, eye color), cellular response or behavior that 
varies between individuals or populations.  
More strictly pertinent to cellular biology, the phenotype can be defined as the expression of a specific 
trait or molecular pattern. In a simplified view we can define as phenotype, all the changes in 
morphology and function that occurs in any single cell as consequence of its internal predetermined 
program (genotype) and the external environment. 
Phenotype is therefore determined to some extent by genotype, or by the identity of the alleles that an 
individual carries at one or more positions on the chromosomes. In case of some purely genetic traits, 
such as classic monogenic diseases (hemophilia, sickle cells anemia, etc.), gene mutations are entirely 
responsible for the final phenotype, whereas in many other, phenotypes are determined by multiple 
genes and influenced by environmental factors. Thus, the identity of one or a few known alleles does 
not always enable prediction of the phenotype. 
The interaction between genotype and phenotype has often been described using a simple equation: 
 
genotype + environment → phenotype 
 
However, the current scientific view is that neither genetics nor environment are solely responsible for 
producing individual variation, and that virtually all traits show a gene-environment interaction. 
 
genotype + environment + gene-environment interaction → phenotype 
 
Gene-environment interaction is a term used to describe any phenotypic effects that are due to 
interactions between the environment and genes. The difference between the two formulas is not of 
marginal importance, since genes and environment can interact in several either additive or non-linear 
ways, making any modeling assumption partially ineffective. Moreover, genes interact each other, as 
well as environmental situations do, making the system extremely complex. Finally random variations in 
gene expression occur in presence of a similar environment. 
Therefore: 
 
genotype + environment + gene-gene interaction + 
 gene-environment interaction + random-variation → phenotype 
 
Other definitions of phenotype: 
 
Definitions from http://ghr.nlm.nih.gov/ghr/glossary/phenotype 
“The observable physical and/or biochemical characteristics of the expression of a gene; the clinical 
presentation of an individual with a particular genotype” 
 
Definition from: GeneTestsThis from the University of Washington and Children's Health System, Seattle 
“The observable traits or characteristics of an organism, for example hair color, weight, or the presence 
or absence of a disease. Phenotypic traits are not necessarily genetic.” 
 
Definition from: National Human Genome Research Institute at the National Institutes of Health 
“Observable characteristics of an organism produced by the organism's genotype interacting with the 
environment” 
 
In conclusion, phenotype can be defined as any detectable characteristic of an organism (i.e., structural, 
biochemical, physiological and behavioral) determined by an interaction between its genotype and 
environment. In other words “genotype” can be regarded as the genetic fingerprint of a particular cell, 
whereas “phenotype” is the outward manifestation of the genotype, conditioned by environmental 
stimula. 
1.4.2   The use of gene expression microarrays for cellular phenotypization 
To maintain homeostasis and function robustly in the face of a changing environment, a cell must 
sense changes in its surroundings and alter its physiology in a compensatory manner. To accomplish 
this task, a number of receptors on the cell surface and within the cell act as sensors for different 
environmental factors (eg, heat shock, hormonal stimulation, inflammation). When these sensors are 
triggered by environmental changes, signals propagate (typically through a network of protein kinases 
and release of second messengers) to the nucleus, initiating DNA transcription in RNA (the operative 
code for protein synthesis). 
This conditional response of the cell leads at the end to changes in its proteins either in terms of 
function or synthesis/degradation. Therefore, changes in environment determine a differential post-
translational modification of proteins, as well as a differential gene expression and protein synthesis. If 
investigating gene polymorphism and aplotypes means exploring the genotype, performing a gene or 
protein expression profiling means ultimately investigating the cellular phenotype. 
Recent complementary advances in genomics knowledge and technology miniaturization are beginning 
to overcome the intricacies of exploring complex diseases and allow to perform a genome-wide 
exploration of the cellular phenotype. 
Advances in robotics, miniaturization, and the development of robust reagents of molecular biology 
have allowed the development of microarrays, which are platforms that allow massively parallel 
screening of RNA or protein abundance with sufficient sensitivity and specificity for each single gene 
transcript. Microarray quantifies the transcriptome or the proteome of a sample of cells as compared to 
a reference sample, and therefore provides a functional measurement of gene expression. 
Microarrays are small, solid supports onto which thousands of different elements (oligonucleotides, 
proteins, cells, cell extracts, and tissues) are immobilized, at fixed locations. The support surfaces are 
usually glass microscope slides. The power of microarray analysis lies in its miniature platform features, 
which facilitates relatively rapid global exploration of the systems studied 
By now gene-expression microarrays can measure around 40.000 different RNA molecules at the same 
time covering the whole genome in a single assay. This technology relies on the 1-to-1 correspondence 
of the Watson-Crick base pair (adenosine always pairs with thymine and cytosine with guanine). Single-
stranded DNA or oligo-fragments of RNA bases (oligomers) of a unique sequence within each gene are 
used as a probe for the presence of that gene within a sample. Direct hybridization of a marked sample 
(or concurrent, competitive hybridization of a marked sample and a reference) with the cDNA or oligo-
mer probe determine a relative proportion between abundance of sample RNA bound to the surface of 
the array and the absolute concentration of the transcript in the sample. Quantitative fluorescent 
labeling of samples from control and experimental groups allows the determination of the relative 
abundance of any gene in a genome. 
Gene expression profiling by microarrays is an especially powerful analytical tool for complex diseases 
because of the multi etiology characterized by a combination of genes involved in development of 
complex diseases. By profiling the global RNA content of any cell, it is possible to monitor in parallel 
all expressed genes to explore any phenotypical abnormalities in diseases.  
Using this technique, researchers have been uncovering rapidly new genes and pathways involved in 
complex diseases and discovering novel treatment targets. Moreover, the microarray technique has 
been shown to be useful for patient management as a precise molecular device for diagnosis, prognosis 
and, personalized treatment, especially in oncology. 
 
 
1.5 Methodological principles of gene expression profiling by 
microarrays 
 
A microarray ‘chip’ consists of thousands of nucleic acid sequences considered to be highly specific for 
target transcripts and working as “probes”, spotted in discrete quantities (each resulting spot is called 
“feature”) on the surface of a microscope glass slide, thus forming an array of spots. 
The basic principles of microarray experiments are the following: 
1) The hybridization of complementary nucleic acids 
2) The spatial discrimination as the way for multiplexing 
3) A probe selection procedure representative of target transcripts 
4) The selective fluorescent hybridization for relative abundance quantization 
 
1.5.1   Hybridization principle 
Hybridization reactions are based on the property of nucleic acid chains to reconstruct a double-strand 
structure when single-stranded: at the right temperature and pH, a strand of nucleic acid will base-pair 
(hybridize) with a strand made of the complementary (or anti-parallel) sequence. This is due to 
hydrogen bonds that form between specific pairs of nucleotides from the opposing strands (adenine 
with thymine and cytosine with guanine). The hydrogen bonds can be disrupted, causing the two 
strands to separate, by heating (a DNA double-strand separates at 95°C). If the double-strand is 
exposed to a temperature sufficient to break hydrogen bonds without disrupting the covalent 
phosphodiester bonds that link adjacent nucleotides together, the DNA sequence is not altered and two 
single-strand complimentary molecules are formed. This process is called “denaturation”. If one were 
to denature a large number of specific DNA segments and then carefully lower the temperature, 
because of the tendency of bases to pair specifically (AT and GC), each strand would hybridize only 
with its complementary partner, perfectly reforming all of the original duplex structures. Thus nucleic 
acid hybridization is sequence-specific and exhibits near-perfect fidelity. 
 
1.5.2   Spatial discrimination 
The physical location of each spot on the array is pre-determined during the design phase and gives the 
correspondence between the measured local fluorescence and the annotation data of the probe-
sequence spotted. Using a laser scan at the proper wavelength it is therefore possible to excite the 
fluorescent labeled sample hybridized to the surface of the array for each individual spot and 
photograph the fluorescent emission. A computer software, called feature extractor, identifies each spot 
because of the discrete intensity of fluorescence compared to local background, measures the 
distribution of the intensity based on a grey-scale (proportional to mRNA abundance in the sample), 
and match the abundance data with the array annotation information. 
 
1.5.3   Probe selection 
Two major techniques for gene-expression microarray probe selection and identification are now on 
the market: 
 cDNA arrays 
 oligo-arrays 
Both of them can now be used for two-color gene-expression arrays. 
The basis of probe selection is to identify relatively small sequences which could be considered as 
uniquely representative of the target transcript. This aim can be achieved using a single-strand cDNA of 
the target mRNA or by synthesizing directly on the array a short (usually 60 bases) sequence known to 
be specific of the target mRNA. The first approach requests the creation of cDNA clone libraries, 
whereas the second needs the identification of unambiguous sequences. 
cDNA clones are prepared individually by amplifying genes of interest from an organism's genome. 
The genes are maintained in a bacterial vector system until the chip is ready to be fabricated. To 
assemble the microarray, the gene inserts are isolated from the bacterial clones and set at designated 
coordinates on the slide, which serves a solid support platform for the hybridization reaction. The 
many probes included in an array can be chosen individually from a database used to store sequenced 
genes and expressed sequence tags, or from commercially available cDNA clone sets. A robotic arrayer, 
designed to manipulate small volumes of solution along three axes with extreme speed and precision, is 
used to assemble each chip. The arrayer places a nanoliter quantity of each probe onto the 
predetermined grid coordinate on the slide (spotting). The probes are immobilized onto the slide after 
each sample has been spotted onto its coordinate. 
Oligo-arrays are prepared by in-situ synthesis, via photolithography, of a short (usually 50-70 bases) 
sequence. Unlike cDNA clones, oligonucleotide probes can be synthesized from sequence data alone, 
so bacterial clone sets do not need to be maintained. Therefore, the major advantages are: the freedom 
of changing sequence as wanted to improve accuracy of hybridization, and the possibility of including 
into the array also genes for what the cDNA is not available in the reference library. Sequences for 
oligos are selected on the basis of public repositories of gene sequences. 
Oligonucleotide arrays are the ‘highest density’ platform of microarrays; an incredibly large number of 
genes can be represented on a single chip using oligos instead of the full length cDNAs. The high 
density of oligo-based arrays allows for the representations of the whole genome and the inclusion of 
redundant probes on the slide, as well as a large number of positive and negative control features.  
 
1.5.4   Concurrent selective fluorescent hybridization 
Microarray measures gene expression as compared to a control sample of reference RNA. 
Total RNA is extracted from a sample of cells of interest, and from the appropriate control sample. 
Then sample and reference RNA can be processed directly or after one or more cycles of linear 
amplification. A cDNA library is constructed from each sample using the RT-PCR reaction with 
random primers to obtain a complete cDNA representation of the original RNA. During reverse 
transcription each cDNA library is separately labelled with a fluorescent molecule. Usually, reference 
cDNA is tagged with the green fluorescent molecule cyanine 3 (Cy3), while sample library is labeled 
fluor-red with cyanine 5 (Cy5). An equal amount of each solution of targets (both experimental and 
control cDNA) are pooled together, denatured, and hybridized to a single chip. Because both libraries 
are incubated together with a single chip, identical targets which are present in both libraries must 
compete for binding sites to their corresponding probe. This is known as competitive hybridization. 
The sample that expresses greater amounts of a given gene (and thus contains a greater number of 
fluorescent targets in the reaction mixture) will competitively inhibit the hybridization of the other 
target. Thus at each coordinate on the slide, red or green fluorescence intensity is directly proportional 
to the amount of target present in one sample compared to the other. The slide, after being washed 
clean of unhybridized reaction substrates, is analyzed with a confocal laser scanner. 
The scanner resolves fluorescent feedback from each coordinate, segregating it into red and green 
channels. The expression of individual genes is then quantified as a relative value, measured as the ratio 
of red-to-green ratio. 
 
Following picture depicts the main steps of a typical dual-color microarray experiment. 
 
Figure 4: Typical experiment workflow for dual-color gene-expression microarray 
 
 
After hybridization, microarray slides are washed, dried, and then scanned. Arrays are scanned with a 
confocal laser scanner that generates beams at the two wavelengths specific for Cy5 and Cy3. The 
fluorescent emission of the slide is converted into two matched digital pictures (one for each 
fluorescent dye) whose degree of grey for each pixel on a 256 levels grey-scale is proportional to the 
fluorescent emission from the area of the array covered by that pixel. Thus at each coordinate, red or 
green fluorescence intensity is directly proportional to the amount of target present in one sample 
compared to the other. After scanning, a typical microarray slide picture is typically represented with 
false colors, with a three-color scale from bright green (the gene represented in the spot is highly over-
expressed in the reference compared to sample) to yellow (the gene is approximately equally expressed 
in sample and reference) to bright red (the gene is highly over-expressed in the sample than in the 
reference). [See following figure] 
 
Figure 5: Dual-color microarray slide represented by false colors 
 
 
The average value of intensity within the same feature, compared to local background signal, is used as 
measure of relative RNA concentration for the transcript represented in that feature. The expression 
level for each gene in the array is described in comparison to the reference sample using the log base 2 
scale, or log2 ratio. 
For example, a gene with a log2 ratio equal to 1 indicates a 2-fold increase in expression (i.e. the mRNA 
transcribed from the gene of interest is present in the experimental sample at twice the levels as 
compared to the control). A log2 ratio equal to -1 indicates a 2-fold decrease in expression, and log2 
ratio equal to zero corresponds to a perfectly yellow point on the slide and thus identical levels of 
expression between samples. 
1.6 Methodological issues related to the use of gene expression 
profile of circulating cells in the study of atherosclerosis (and 
other chronic complex diseases) 
 
When narrowing down which cell type is optimal to be used as biosensor for cardiovascular disease, 
several standpoints can be taken. One is that one uses the whole leukocyte population. Cardiovascular 
risk factors could well shift the balance between the various populations of cells, however, one could 
support the view that it is not so much the cell type per se, but the expression level of all cells in the 
blood resembles the influence of the atherosclerotic process. In other words, if, for example, the 
uremic state causes oxidative stress which can induce an inflammatory response in a variety of cell types, 
it may not be so relevant to know which cell type exactly contributes to this inflammatory response, 
merely it matters that the expression of particular cytokines is modulated. As such, the entire cell 
population can serve as biosensor. A trade-off may be that modulation of gene expression in a small, 
relevant subset of the cells may be ‘diluted’ by a large number of other populations of which the gene 
expression remained unaltered. One could also take the point of view that, to obtain more precise 
insight in the process of atherosclerosis, specific information is needed from subtypes of cells which 
form the effector cells for the process. Monocytes that are heavily involved in initiation of arteriole wall 
damage, which first becomes visible as a fatty streak, may be the cell type of choice to study very early 
atherosclerosis. Lymphocytes, and perhaps also granulocytes, may be more relevant cells to study once 
atherosclerotic lesions are already formed. Furthermore, one could envision that selecting a circulating 
cell subpopulation which displays phenotypical changes heralding invasion of the arterial wall, such as 
increased surface expression of adhesion molecules could yet further improve the specificity of the 
information supplied by gene expression analysis. However, based on a trade off between relevance for 
CVD pathogenesis and relative simplicity of specimen processing, peripheral white blood cells or 
mononuclear cells (lympho-monocytes or PBMCs) appear to be the most suitable targets. 
 
1.6.1   Reproducibility of WBC/ PBMC gene expression analysis by 
microarrays 
An obvious question that has developed is whether gene expression in circulating cells, specifically 
leukocytes and peripheral blood mononuclear cells, is stable. Three studies have been performed, with 
the same overall conclusion. One study assessed temporal changes in individual gene expression 
patterns in whole blood using microarrays and in peripheral blood mononuclear cells, and concluded 
that inter-individual gene expression modulation is much more prominent than intra-individual gene 
expression [22]. More in detail, the authors used a two-way ANOVA approache to analyze inter-
individual and intra-individual gene expression differences. The following graph shows the distribution 
curve of the number of differentially-expressed genes for each given ANOVA F-value. 
 
Figure 6: Individual-specific variation of gene expression in peripheral blood leukocytes 
Day-specific genes 
Individual-specific genes 
 
 
As it appears from this representation, the use of a sufficiently restrictive definition of “differential 
expression” (in this case an F-value approximately above 20) identifies a group of genes that are 
different between groups without false positive genes related to intra-individual daily variations in gene 
expression. In addition, the following picture shows the results of a 2D-Hierarchical Clustering analysis 
operated on these data, performed to assess whether the main determinant in variability of gene 
expression data was the intra-individual or inter-individual expression patterns. 
 
Figure 7: 2D-Hierarchical Clustering of intra-individual VS inter-individual gen e expression profiles 
 
Footnote to figure. Two-dimension hierarchical clustering of gene expression data in Radich et al. experiment. Each row 
represents a sample and each column a gene. Different specimens from the same subject are collected in different days and 
are represented in different rows using the same color. Each color corresponds uniquely to a subject. 
 
As it clearly appears from the picture, different samples form the same subject perfectly cluster together 
indicating that it is the inter-individual variability that drives the composition of the clusters. This is of 
high relevance as the clustering technique is by definition unsupervised and therefore no comparison or 
pre-analytical assumption can be made to force the identification of the clusters. It is the distance 
matrix that discriminates the similarities and differences among samples that start all from a single large 
cluster as H0 hypothesis. 
Another study in peripheral blood leukocytes confirmed these findings and also analyzed whether 
immediate processing of the samples was necessary; indeed the individual profiles slowly disappeared 
through time, indicating that immediate processing of the samples is necessary to obtain these stable 
results [23]. Finally, a study assessed gene expression variation in peripheral blood mononuclear cells 
solely and also concluded that intra-individual variation is not very pronounced [24]. Shared between 
two of the studies is that several of the genes that appear to have the greatest intrinsic individual 
variation. PBMCs are also known to have highly polymorphic sequences; this supports that variation 
and expression of these genes reflects an underlying allelic variation in their regulatory sequences [23]. 
Taking a look at these studies it is very encouraging for the use of leukocytes as biosensors. 
Nevertheless, the methodological issue will remain in that in a population where gene expression 
patterns are derived from people with disease states, a suitable reference pool has to be available.  
 
1.6.2   Collection and processing of circulating cells 
It is self evident that circulating cells are easy to access, and therefore isolation and manipulation of 
specimens is apparently free of problems. However, peripheral blood contains several populations of 
mature white cells with an uncountable number of sub-populations each one requiring a different 
isolation protocol. In addition, there is clear evidence that also differentiated red blood cells and 
platelets hold significant amount of total and messenger RNA [25]. Erythrocyte RNA is extremely 
abundant in whole blood samples, and globin A1 is the most expressed gene, as shown in the next 
figure [26]. 
 
Figure 8: Top expressed genes in whole blood samples 
 
 
In the context of this complexity, two opposite tendencies in RNA isolation for microarray studies are 
emerging: on one side, there is the attempt to use whole blood specimens, on the other the effort to 
identify the population or sub-population most representative of the disease process. 
Protocols for RNA extraction from whole blood aim at reducing sample manipulation. This approach 
has the double advantage of decreasing the delay between specimen extraction and RNA stabilization/ 
isolation, and of decreasing the complexity of the pre-analytical procedures to a level suitable for 
hospital laboratories and clinical practice. This latter is of major importance in multi-center clinical trials 
and large-scale population studies, where the effort required to isolate subpopulations from peripheral 
blood and to stabilize RNA right after blood withdrawal can be overwhelming and often unrealistic, but 
there is clear evidence showing that adequate sample handling is of paramount importance to prevent 
ex vivo transcriptional changes [27,28]. 
 
Whole blood RNA collection systems are commercially available as specialized Vacutainer tubes 
containing a proprietary reagent that stabilizes intracellular RNA for days at room temperature and 
weeks at 4° C, reducing the need of immediate processing and/or freezing. The PAXgene system 
(PreAnalytiX, Hombrechtikon, Switzerland) has been shown to stabilize RNA [ 29 ], prevent its 
degradation [30] and provide high-quality sample for RT-PCR [31] applications. However, when 
compared to white blood cells, total RNA from stabilized whole blood specimens shows much lower 
signal-to-noise ratio (as demonstrated by reduced overall present call rates in single dye arrays [27]) and 
inferior data quality (as assessed by increased intragroup variance [32]). The high abundance of globin 
mRNA has been suggested to account for these limitations [26] and RNase H digestion protocols or 
erythrocyte-depletion systems have been showed to greatly improve reproducibility, variance, and 
signal-to-noise ratios in whole blood specimens [33,34]. However these protocols are complex and 
require an extra work, currently not easy to standardize. 
 
Based on this information, the isolation of total white blood cells provides a more robust sample with 
better array performance. In fact, when systematically compared [26], leukocytes and whole blood 
samples show a similar reproducibility (Pearson’s correlation coefficient for replicates higher than 0.985 
for both), but a quite different ability to detect changes in gene expression. Whole blood RNA 
discriminates between normal and pathological samples (trauma patients) with less accuracy, and 
provides a lower differential signal after stimulation with Staphylococcus enterotoxin B compared to 
buffy-coat RNA. As mentioned above, these findings can be partially explained by the extreme 
abundance of erythrocyte/ reticulocyte-specific transcripts (such as globin genes) that do not change in 
response to the external environment and impair the performance of discrimination and clustering 
analyses. 
 
Looking at published data in general, it is evident that both whole blood and leukocyte isolation 
protocols generate high-quality RNA, but their impact on transcriptome results is significantly different, 
raising major concerns for the possible use tout-court of blood-based systems in clinical research. 
However, despite a quite clear superiority of white blood cell RNA as biological matrix for high-
throughput microarray studies, it should be kept in mind that the technical procedures to obtain an 
uncontaminated buffy-coat sample (including centrifugation, erythrocytes and platelets lyses, washing, 
and re-suspension) are not of routinely use in clinical research. 
In addition, white blood cells are a complex population comprising a variety of cell types (T-cells, B-
cells, monocytes, NK cells, and granulocytes), each of which can be further subdivided (Th1, Th2, 
neutrophils, eosinophils, etc.). It is without dispute that the relative proportion of these subpopulations 
displays variations upon physiological stimuli, upon disease processes, and in response to treatments (i.e. 
corticosteroids). Their involvement in the pathophysiology of the disease is also not homogeneous: 
granulocytes, for instance, are the most abundant white blood cells subpopulation (about 50 to 70% in 
healthy adults), but their role in vessel atherosclerosis is minimal compared to monocytes or 
lymphocytes. Therefore, granulocytes can be either non-representative of the disease process or 
influenced by other sources of inflammation. For this reason, granulocytes are often removed from 
buffy-coat and mononuclear cells selected for RNA extraction. Peripheral blood mononuclear cells 
(PBMC) are an enriched preparation of monocytes and lymphocytes. Their relationship with CVD 
pathophysiology is more stringent than total WBC and therefore they appear to be a highly 
representative sample, but the isolation procedure is complex and delicate because of the large sample 
processing request after blood drawn. 
 
In addition neither PBMCs are a single population and their composition includes several highly 
polarized cell types whose proportion is also highly variable: monocytes range from 2 to 10% of 
PBMCs, T- and B-lymphocytes vary from 61-85% and 7-23% respectively, and also the ratio between 
CD4+ and CD8+ T-cells ranges from 1.0 to 2.0 [35]. This difference and variability in the relative 
proportions of WBC subpopulations is not trivial and could potentially affect the composite gene 
expression profiles of whole blood or unfractionated PBMCs. Palmer and colleagues [36] performed a 
microarray analysis of purified subpopulations of peripheral blood cells, and were able to identify highly 
specific gene expression signatures for B-cells (427 genes), T-cells (222 genes), CD8+ T-cells (23 genes), 
granulocytes (411 genes), and lymphocytes (67 genes), indicating a high level of heterogeneity among 
PBMC sub-populations. Moreover, these differences are more prominent than the differences in gene 
expression profile between individuals in unsupervised clustering analyses, showing that subpopulation-
specific genes have a greater impact on transcriptome than person-specific genes. In other words, 
changes in the proportion of sub-populations could affect statistical analysis more than changes in the 
composition of the study population. In addition major differences in gene expression could also be 
present in polarized subgroups of cells within the same sub-population. For instance, T cells 
subpopulations share a large number of commonly expressed genes, but a comparison within CD4+ 
cells shows that more than 100 genes are differentially expressed between Th1 and Th2, and this list 
includes not only genes associated with cell polarization, but also cytokines, transcription factors, 
molecules involved in cell migration, and genes with unknown function, not previously associated with 
differences in T cells subpopulations in pre-array studies [37]. 
Finally, the role of a cell population can vary overtime in the pathophysiology of a disease: if it is clear 
that lymphocytes and monocytes are highly involved in atherosclerosis development, there is also 
evidence that during the first 24 hours after an acute cerebrovascular event gene expression in 
polymorphonuclear leukocytes changes to a higher extent than in monocytes, being perhaps more 
representative of the acute response to injury [38]. 
 
1.6.3   Reference selection for two-color arrays 
Together with the choice of an adequate biological sample, representative of CVD risk, the use of two-
color arrays (microarrays that use two samples, a test and a reference,  labeled with two separate dyes) 
raises the fundamental question of the selection of an adequate reference sample. This choice is not 
trivial and influences the possibility to make comparisons across laboratories, platforms, and 
populations. The definition of a common reference for two-color array studies would favor the 
integration of different datasets and would provide a set of basic values to compare raw data with one-
color arrays. However, so far no clear standard for referencing has emerged and two opposite strategies 
have been proposed: the use of a “tissue-based reference” extracted from the same tissue of the 
samples, and the development of a “universal reference” suitable for any tissue. However, these two 
choices imply two diverging philosophies of array data interpretation and pose different issues to the 
statistical analysis. The “tissue-based” strategy identifies a reference RNA as close as possible to the 
sample but from “normal” tissue, prepared either from cell lines or mixing RNA samples from tissues 
of normal donors. This approach implies the possibility to unequivocally define a “normal” sample 
(which can be not easy in studies oriented to cardiovascular risk), and the risk to end up working with 
very small differences between sample and reference, and therefore with log-ratios too close to 0. 
However, this strategy makes log ratio values directly interpretable without the need to compare the 
expression data with other samples to obtain meaningful information on differential expression. 
 
On the other hand, the “universal-reference approach” is based on the principle that a perfect reference 
should be able to produce the maximum yield of positive spots throughout the array, and therefore the 
choice of the reference is array-based, instead of sample based. In this context, the perfect reference for 
whole-genome human arrays would hold significant amount of mRNA for any human gene. Since there 
is no single tissue able to express the whole genome, pooled RNA from multiple cell lines are usually 
employed [39]. This approach makes expression data not directly interpretable because the intensity 
values of the sample are normalized with a completely unrelated reference RNA, but allows to handle 
greater log ratio values for the statistical analysis, and virtually to directly compare data from different 
tissues. 
 
In conclusion, there is no consolidated standard or guideline to help with the choice of the best sample 
and the best reference in blood-based transcriptomic studies, and further data are needed to better 
define: 1) the blood cell population most representative of any manifestation of CVD, 2) the best 
protocols for RNA isolation, and 3) the most advantageous reference strategy for inter-array and inter-
sample data comparison. 
 
 
1.7 Disease profiling by gene expression analysis in circulating 
cells 
 
Based on what discussed in the previous sections, gene expression profiling in circulating white blood 
cells has a clear rationale as multi-marker strategy in personalized CVD risk assessment, and it is time to 
move to test this approach in a clinical research context. As functional biological marker, the high-
throughput approach to CVD risk has the potential to provide not only a measure of the exposure to 
CVD risk, but to reflect the degree of physiological and biochemical response to the exposure. Clearly, 
at this stage, there are no definitive evidences pro or against this vision, but in the last years several 
observations have pointed to support this general hypothesis. In addition, a similar approach has been 
implemented in hemato-oncologic disorders, and also other diseases without a circulating cellular 
component. Characteristic blood transcriptomic patterns have been identified for infective, auto-
immune, neurological and psychiatric diseases, and for environmental exposure to toxic substances. 
The following table shows a revision of the published literature in this field. 
 Table 2: Studies demonstrating a correlation between clinical features of a disease and gene expression profile in 
circulating cells 
Disease 
Referen
ce 
Transcriptome 
correlates with 
clinical 
phenotype* 
Diagnostic 
proof-of-
concept † 
Prediction of 
outcome or 
response to 
treatment ‡ 
Neurological diseases 
Migraine headache 40 X   
Tourette syndrome 41 X  X 
Multiple sclerosis 42 X  X 
Neurofibromatosis type I, 
Tuberous sclerosis type II, Down 
syndrome 
43 X X  
Huntington chorea 44 X X  
Alzheimer 45 X   
Psychiatric diseases 
Post-traumatic distress 46 X X  
Psychological stress 47 X   
Solid neoplasms 
Renal cell carcinoma 48,49 X X X 
Toxic Exposure 
Benzene 50 X   
Lung diseases 
Asthma patients 51 X  X 
Pulmonary hypertension 52 X X  
Infective diseases and vaccination 
SARS 53 X   
Influenza immunization 54 X   
HIV 55 X X  
Allergic diseases 
Contact dermatitis 56 X X  
Allergic rhinitis 57 X X X 
Disease 
Referen
ce 
Transcriptome 
correlates with 
clinical 
phenotype* 
Diagnostic 
proof-of-
concept † 
Prediction of 
outcome or 
response to 
treatment ‡ 
Autoimmune diseases 
Rheumatoid arthritis 58,59,60 X X  
Systemic sclerosis 61 X X  
Systemic lupus erythematosus 62,63,64 X  X 
Inflammatory bowel disease 65 X   
Other systemic diseases 
Chronic fatigue syndrome 66 X X  
Sarcoidosis 67 X   
Aldosteronism 68 X   
Sickle cell disease 69 X   
Trauma 19 X X  
Footnote to table. The table contains bibliographic references for non-cardiovascular diseases whose peripheral blood 
transcriptomic profile has already been investigated with high-throughput microarrays. Table also indicates with a “X” 
sign for each study whether: * a differential gene expression profile for the disease has been identified; † the study reports a 
classification analysis showing that gene expression profile can accurately identify the disease, and ‡ pre- and post- or with 
and without treatment groups with the same disease have been compared or a clinical outcome recurrence has been verified. 
 
The presence of highly specific gene expression patterns in circulating cells representative of diseases of 
different organs suggests that WBC behave as biosensors whose gene expression is influenced by 
circulating molecules produced in other organs. As such, gene expression of blood cells might 
“represent” pathological processes developing in any body system, giving valuable diagnostic and 
prognostic information. Preliminary data show an interesting degree of concordance in gene expression 
between WBC and certain tissues (i.e. central nervous system), based on sharing similarity in gene 
expression network of receptors and mechanisms of transduction [70,71]. 
 
To demonstrate that transcriptome profiling has the potential to describe the systemic cellular 
phenotype and to provide personalized, clinically-relevant information, several principles must be 
proved: first, it should be demonstrated that genomic data re-confirm consolidated notions on CVD 
risk. This point implies showing a different transcription fingerprint in presence of the disease or 
different phases of the disease, and after exposure to known risk factors. That means that transcription 
profiling should serve as diagnostic tool (case patient identification), as well as risk stratification strategy 
(high-risk individuals identification). In addition, a transcription profile is expected to change 
dynamically in presence of acute CVD events, to be predictive of future clinically relevant events, and 
to be modulated in presence of treatment. We need, therefore, to reproduce first already known 
information and to observe already expected changes in risk after treatment. These descriptive results 
should also be consistently related to the pathophysiological background of each one of these scenarios, 
and therefore observed gene expression modulation should fit in seamlessly. 
After this preliminary observations, it needs to be demonstrated that gene expression profiling provide 
further (and more personalized) information than what carried by classical risk factors and mono-
marker strategies. In other words, a transcription profile of circulating cells should improve the 
coverage of knowledge beyond the limits intrinsic to the clinical and current singular biomarker 
approach. In this context, deviations from the information given by clinical risk factors are expected, 
and personalized profiling should effect a quantum leap in CVD prediction/ prognosis when compared 
to current risk stratification algorithms. The gene expression profile is also expected to partially change 
during treatment (markers of drug response), but also to be in part unaffected providing an accurate 
quantification of the residual risk. 
Finally, we expect that gene expression can accurately identify the fingerprint of a disease, also among 
other conditions with similar pathophysiological mechanisms and therefore be able to distinguish CVD 
from other pro-inflammatory states such as autoimmune or infective diseases. Similar discrimination 
power should be provided among different causal factor for a common clinical phenotype. For instance, 
a fingerprint for high cholesterol-related CVD should be distinguishable from the diabetes or smoking-
associated CVD signatures. 
 
So far, preliminary evidences are available as proof-of-concept that individuals with acute CVD events 
are different in leukocyte transcriptomic profile compared to healthy controls [72,73,74,75], that 
exposure to risk factors is associated with abnormal gene expression [76], and that treatment can 
partially revert these alterations [77,78,79,80]. Classification and diagnostic evidences have also been 
provided [81]. However, no proof studies are available on prognostic significance of microarrays in 
preventive cardiology, and the published literature is still addressed to the average behavior of genomic 
profiles, instead of working with single-patient unique phenotype. 
The following sections describe the available proof-of-concept data, and clearly suggest that blood 
leukocyte fingerprint can be used in several clinically relevant situations as surrogate for other tissues, 
providing markers of disease/ treatment and new insights into the disease pathophysiology and drug 
mechanism of action. 
 
1.7.1   Gene expression profiling can portray acute cardiovascular events 
Preliminary animal studies suggested that acute cerebral injuries of different origin (ischemic stroke, 
intracerebral hemorrhage, status epilepticus, and insulin-induced hypoglycemia) are portrayed by a 
different gene expression profile in circulating cells compared to control animals [73], and that the 
genomic signature univocally identifies the type of injury [74]. 
 
Although only little information is available in humans, published data clearly show a different 
transcriptomic profile in presence of acute stroke compared to control subjects [72,73]. Moore and 
colleagues evaluated the peripheral blood mononuclear cell (PBMC) gene expression profile during the 
acute phase of 19 patients with CT confirmed stroke and 19 controls to investigate whether a systemic 
genomic signature could be demonstrated as fingerprint of acute cerebro-vascular event [75]. 
About 200 genes resulted differentially expressed in stroke patients, even though a quite conservative 
approach for comparison was used, including multiple comparison corrections, false discovery rate 
conservative setting, and permutation analysis. Moreover, the selection of a highly representative set of 
22 genes by Prediction Analysis for Microarrays (PAM) [82], a supervised classification algorithm based 
on shrunken centroids, allowed to distinguish between cases and controls with high accuracy 
(Sensitivity 89%, Specificity 95%). When the small PAM-selected list of genes was retested in an 
independent cohort (9 cases and 10 controls), the classification performance still resulted in 78% 
sensitivity and 80% specificity. 
In addition to this proof of concept of the possible role of transcriptomic signatures for diagnostic 
purposes, it is of interest to note that, looking at the results at large, several broad classes of genes 
differentially expressed in stroke patients were related to leukocytes activation and differentiation, 
response to hypoxia, vascular repair, and included genes potentially associated with an altered cerebral 
microenvironment. Clearly PBMCs were neither hypoxic themselves nor in a hypoxic environment, but 
in any case they were able to “sense” and represent the ongoing ischemic insult to the brain tissue 
(hypoxia reaction genes), suggesting the presence of a local or systemic signaling. It is even more 
interesting to note that stroke vascular risk measured by the Framingham score accounted for about 
28% of the variance of the gene expression profile in the group of acute ischemic stroke patients as to 
emphasize that transcriptomics may provide an accurate snapshot of an acute CVD event, and this 
representation has only partial  overlap with the one portrayed by classical risk factors. 
 
1.7.2   Gene expression profiling in presence of environmental exposure to 
smoking 
Smoking is a clear and strong environmental factor with the highest probability of yielding a detectable 
and repeatable signature in white blood cell transcriptome among the classic risk factors for CVD. In a 
recently published paper, authors [76] identified 42 smokers and 43 non-smokers based on self-
reported questionnaire and confirmed by plasma concentration of cotinine, a stable metabolite of 
nicotine. The two groups of subjects were fairly well matched for clinical profile of CVD risk factors 
and demographics, and more than 800 genes where identified as signature of smoking exposure. 
Differentially expressed genes were then ranked in descending order by the absolute value of Pearson’s 
correlation to plasma cotinine concentration with the aim of identifying a small predicting set to classify 
smokers and non-smokers (as shown in the next figure). 
 
Figure 9: Heatmap of differentially expressed genes between smokers and non-smokers 
Training
set
 
Footnote to figure. The heatmap shows the relative expression value of most differentially expressed genes in smokers 
compared with non smokers. Each column represents a gen and each row a subject. Smokers are represented in white 
(open boxes) and non-smokers in black (filled boxes). 
 
The final set of 36 top candidate genes (27 directly and 9 inversely correlated to cotinine levels) was 
defined based on total misclassification error minimization algorithms and performed with 81% 
sensitivity and 88% specificity. 
A test set of 10 smokers and 10 nonsmokers, both cotinine confirmed, was used for model validation 
in two different time points yielding an impressingly high accuracy (about 90% sensitivity and 100% 
specificity in both occasions) and showing great consistency and stability over the time, as shown in the 
next figure. 
 
Figure 10: Accuracy of  gene expression markers in the identification of smokers 
Test
set 1
Test
set 2
 
Footnote to figure. The heatmaps show the relative expression value of most differentially expressed genes in smokers 
compared with non smokers in the training set, when tested in two test sets. Each column represents a gen and each row a 
subject. Smokers are represented in white (open boxes) and non-smokers in black (filled boxes). 
 
This study clearly demonstrates that the presence of a highly-defined clinically-relevant phenotype 
(chronic exposure to cigarette smoking) can be accurately identified on the basis of mRNA expression 
in peripheral leukocytes, which are neither the toxicological target for nicotine nor directly exposed to 
cigarette smokes. 
 
1.7.3   Gene expression profiling after treatment 
Biologically relevant gene expression signatures for pharmacological treatment have also been 
demonstrated with high-throughput techniques. Expression profiling in hypertension research has risen 
high expectations on the one hand [83], and has evoked criticism on the other hand [84]. The optimistic 
view envisioned physiological genomics as a tool to unravel pathways in hypertension, and to guide 
therapy (i.e. pharmacogenomics); critics argued that the likelihood that gene profiling experiments 
would lead to the discovery of new, relevant pathways was low and that the value of time course  
experiments in experimental hypertension was limited [84]. In a small pilot study gene expression 
profiles of leukocytes of patients with essential hypertension were compared with profiles obtained 
from leukocytes of carefully-matched healthy control subjects [78]. Subjects were matched for age and 
body weight; smoking subjects were excluded from the experiments. Cholesterol, glucose and 
creatinine levels were not different. The leukocytes of the essential hypertensive patients revealed 606-
differentially-expressed genes. Genes of interest included a group of genes involved in chemotaxis, a 
number of cytokine receptors, and a number of genes involved in transmission of cytokine signals. Also, 
interestingly, the AT1 receptor displayed an increased expression level, which was confirmed by 
conventional RT-PCR analysis. Most remarkably, the vast majority of changes observed in the 
untreated group were not any more visible in a separate group of treated patients. It should be 
remarked that in this pilot study RNA within groups was pooled to obtain sufficient material for 
microarray analysis and no conclusions can be drawn about individual expression levels.  
 
In a relatively recent study [79], 11 male patients with primary hyperlipidemia were treated with 
Atorvastatin, 20 mg daily for 4 weeks, yielding an average decrease in LDL cholesterol of 40%. Blood 
specimens were collected at baseline, after 12 and 36 hours from the first drug administration, and after 
1 and 4 weeks of treatment. PBMC gene expression was evaluated at all time-points with the aim of 
investigating early and late effects of statins. A total of 240 genes were significantly regulated by 
atorvastatin during the 4 weeks of study, and the differential expression signature for anti-dyslipidemic 
treatment included several genes involved in hemostasis, inflammation and other processes critical to 
atherosclerosis. 
As expected, LDL-cholesterol levels did not significantly change within the first 36 hours of treatment, 
but 48 genes were already differentially regulated after 12 h and 75 after 36 h, as shown in the next 
figure. 
 
Figure 11: Effect of Atorvastatin treatment on gene expression profile in WBC 
Differentially expressed genes
↓ 40% LDL after 4 weeks
LDL-cholesterol levels did not significantly
change within the first 36 hours
 
 
Since no significant effect on plasma lipid levels was detectable at these time-points, it is likely that the 
atorvastatin-induced modulation of gene expression was independent of lipid-lowering. Then, 58 
additional genes resulted differentially regulated after 1 week and 121 after 4 weeks of treatment, when 
plasma lipid levels were significantly decreased, and therefore these changes in gene expression may be 
secondary to lipid lowering. The presence of different patterns of response to atorvastatin over time 
suggests that its impact on gene expression, and therefore cell biology, implies both lipid-dependent 
and independent effects. Since it is debated whether the cardioprotective effect of statins goes beyond 
its action on cholesterol synthesis and lipid homeostasis [80], microarray studies with adequate time 
course design can provide original, descriptive and, most important, in-vivo insights into cell 
pathophysiology and advocated pleiotropic effects. 
 
Further evidence that circulating cell gene expression profile can serve as functional biological markers 
of drug exposure with a clear link to disease pathophysiology is provided by the results of an 
unsupervised hierarchical clustering performed on this repeated-measures study to identify possible 
functional/ temporal associations. Clustering approach identified a group of genes associated with 
proinflammatory effects that resulted upregulated soon after the start of treatment and then 
progressively down-regulated over-time. These genes were all functionally inter-related and involved in 
INF-alpha response pathway. This apparently surprising observation is supported by in vitro studies 
showing that lipophilic statins (such as atorvastatin) induce a transient proinflammatory response in 
monocytes [81]. 
 
2  Study design and aims 
 
 
2.1 Aim of the project 
 
Based on the scientific background provided in the previous chapters, we decided to provide 
preliminary data to assess the presence of a relationship between gene expression profile in circulating 
PBMCs and the presence of cardiovascular risk factors in apparently healthy young-adults without 
significant diseases or chronic pharmacological treatments.  
As already outlined, most of the available data were reported by single research groups, often in 
underpowered samples and almost never at a whole genome level. For this reasons, we intended to 
verify whether the gene expression profile of circulating PBMCs had pro-inflammatory features in 
subjects at low risk with moderate exposure to CVD risk factors, assessing the expression profile at 
whole genome level in a relevant cohort of subjects. 
 
 
2.2 Study design and phases 
 
The conducted study is a monocentric, observational, cross-sectional study. The study activities were 
carried out in two different time periods.  
In the first instance, a small pilot was conducted in 50 healthy subjects to pilot the expression profile 
results and decide whether to collect data from a larger cohort. Then, this pilot experience was followed 
by a larger, confirmatory recruitment effort.  
The overall size of the enrolled population is 167 individuals of both genders. Data here reported are 
from all enrolled subjects. 
 
3  Population and selection criteria 
 
The study population included a total of 167 apparently healthy volunteers of both genders, all young 
adults (18-65 years) without medical history or clinical findings of major chronic diseases and not 
undergoing any pharmacological treatment. 
 
 
3.1 Population screening 
 
Participants were selected as offspring of volunteers attending the Barilla study, an epidemiological 
survey started in 1981 to investigate several aspects of the impact of insulin resistance on human 
disease [85,86]. To recruit the “Barilla Offspring” population, a letter was sent to all the 422 parents 
who attended the last follow-up visits [87] asking them to inquire the interest of their offspring to 
participate into the study. A total of 179 offspring accepted the invitation and were screened.  
 
The following flow-chart depicts the Barilla offspring cohort. 
Figure 12: Barilla Offspring cohort  flowchart 
 
 
Out of the 179 screened subjects, 12 did not meet the inclusion criteria for presence of concomitant 
diseases. The first 50 subjects meeting the inclusion criteria were included in a pilot dataset whose gene 
expression profiling was performed before completing the enrollment of the overall cohort.  
The following flow-chart shows patient’s disposition in the study. 
Figure 13: Barilla Offspring cohort disposition 
 
 
Subjects have been fully informed on the aims of the study, experimental design and study procedures 
in order to sign the consent form. The study was approved by the local institutional ethic committee. 
All screened subjects signed the consent form before participation. 
 
 
3.2 Selection criteria 
 
During the screening visit, the following inclusion and exclusion criteria were checked. Only subjects 
meeting all the inclusion and none of the exclusion criteria were enrolled. 
 
3.2.1   Inclusion Criteria 
Patients with the following inclusion criteria entered the study: 
 
 Both genders; 
 Age >= 18 or < 65 years; 
 For women: being in the fertile age (as defined by presence of menses in the last 6 months); 
 Absence of major diseases or other medical exclusion criteria enlisted below; 
 Daily alcohol intake below 80 gr 
 Written informed consent to participate into the study 
 
3.2.2   Exclusion Criteria 
 
Patients with at least one of the following exclusion criteria entered the study: 
 Age < 18 or > 65 yrs 
 Postmenopausal women  
 Pregnancy 
 Previous cardiovascular events  
 Type 1 or type 2 diabetes 
 Medical history of malign cancer, or ongoing cancer disease with the exception of skin cancer 
(excluding melanoma) and thyroid cancer (excluding medullary and anaplastic histotypes) 
 Acute illness  
 Autoimmune or inflammatory chronic illness  
 Organ failure or severe systemic illness 
 Psychiatric illness or diseases possibly causing a poor compliance to the study protocol 
 Drug addiction or alcohol intake> 80 gr/day 
4 Study visits 
 
After direct phone interview with the volunteers to rule out evident screening failures, subjects were 
invited for a first meeting during which investigators provided exhaustive information on the study. If 
the subject was interested in participating into the study, the informed consent was signed at this time 
and the volunteers entered the screening procedure. If all inclusion and none of the exclusion criteria 
were met, the subject was enrolled and two further appointments were scheduled (visit 1 and visit 2). 
The following table shows the content of the three study visits. 
 
Table 3: Content of the study visit 
Visit Tasks 
Type of parameters 
recorded 
Screening 
 Subject’s information 
 Signing of the informed consent 
 Unique ID assignment 
 
Metabolic visit 
(V1) 
 Personal and medical data 
gathering 
 Physical examination 
 Fasting blood drawn 
 Urine collection and storage 
 Oral Glucose Tolerance Test 
(OGTT) with multiple blood 
drawn 
 PBMCs isolation from 
peripheral blood and storage 
 RNA extraction from a PBMC 
aliquote 
 Personal and family 
medical history 
 Clinical data 
 Laboratory data 
 PBMC samples 
 RNA for array 
hybridization 
Cardiovascular 
visit (v2) 
 Carotid ultrasound 
 Intima-Media 
Thickness (IMT) 
 
The content of the three visits is here described in more detail: 
 
4.1 Screening visit (V0) 
 
Study information 
Subjects were personally and exhaustively informed by the investigators about the aims, procedures, 
possible risks and timeline of the study. The informed consent was  red and commented together with 
the investigators.  
 
Signing of the informed consent and ID assignment  
The informed consent was signed in duplicate both by the participant and the investigator in the 
presence one of the other. One copy was given to the participant and one copy stored in the study 
records. An unambiguous consecutive ID number was assigned to each single participant. 
 
 
4.2 Metabolic visit (V1) 
 
Participants were scheduled at 8 o’clock in the morning, fasting, without taking any medication. The 
metabolic evaluation was performed at Parma University, Department of Internal Medicine and 
Biochemical Sciences.   
 
Fasting blood sample collection 
Twelve hours fasting venous blood samples were collected and subjects asked to refrain from smoking 
and drink coffee the morning of the visit. 
The following biochemical evaluations were performed: 
• Hemocytometric analysis and full blood count 
• Glycemia 
• Lipid profile 
 - Total cholesterol 
 - HDL cholesterol 
 - Triglycerides 
• Liver enzymes (AST, ALT, gammaGT, ALP) 
• Uric acid 
 
The concentrations of glucose, insulin, total cholesterol, high-density lipoprotein-cholesterol (HDL-C) 
cholesterol, triglycerides (TG), AST and ALT were quantified as previously described [88]. Low-density 
lipoprotein-cholesterol (LDL-C) was calculated using Friedewald’s Formula. 
 
Plasma / urine storage 
Plasma and 24 urine collection samples were stored at -80°C in order to create a “sample bank” for 
post-hoc biochemical analysis. 
The following parameters were measured on stored samples: 
• Plasma insulin concentration 
• Nitrates/nitrites (as index of overall nitric oxide plasma concentration) 
• Adhesion molecules (such as ICAM-1, VCAM-1, E-Selectin) 
• High-sensitivity PCR (Hs-CRP) 
• Urine 
• Microalbuminuria, urine proteins 
• Urine creatinine 
 
Oral Glucose Tolerance Test (OGTT) 
A baseline, fasting blood sample was drawn. Subjects were then given a glucose solution (75 gr) to be 
drunk within 5 minutes. Blood samples were drawn at prefixed intervals (30, 60, 120 minutes) after 
glucose ingestion to measure glucose and insulin levels. 
 
Personal and medical history data collection 
A complete medical history and physical examination was conducted as previously described [89]. 
 
Anamnestic data were collected with a questionnaire using close or semi-close questions and the 
investigator entered data in an electronic CRF. 
 
Personal data collected to be analyzed included: 
Personal medical history:   
1) Synoptic variables concerning the main cardiovascular diseases, risk factors, and metabolic 
disturbances (this list of question served as double check on the inclusion criteria delineate 
above) 
2) Systematic information of any past or present disease of any kind using a validated international 
classification code (International Classification of Diseases v9, ICD-9). For any disease or 
pathological condition, starting and (if applicable) ending dates were also collected 
 
Family history with close question aiming to prevalence of major cardiovascular diseases and risk 
factors in first degree relatives, including 
 Diabetes and glucose intolerance 
 Dyslipidemia and hypertension 
 Heart, brain and peripheral vascular diseases 
 
Personal habits and lifestyle, including: 
1) Smoking. The following data were recorded: smoker/ non smoker/ past smoker, cigarette/ 
cigar/ pipe smoking, years of smoking, number of cigarette/ cigar smoked per day, packs/ year 
of smoking, years since quitting (if applicable) 
2) Alcohol intake. The following data were recorded: daily alcohol/hard liquor consumption with 
gram calculation. Data from this questionnaire were afterward matched with more accurate 
estimation of alcohol consumption from 7-day food intake records and overall diet food 
frequency questionnaires on macronutrients and major micronutrients intake. Alcohol intake 
was estimated by frequency assumption questionnaire and expressed as grams per week. We 
considered 12 g of alcohol from a glass of wine, and 13 g from a can of beer or from a small 
glass of spirits. 
3) Physical exercise. The following data were recorded: weekly physical activity estimated using a 
validated questionnaire, taking into account both work-related and leisure physical exercise 
 Physical examination 
A complete physical examination was performed, including heart, vessels, chest, abdomen, and lymph-
node exploration. Anthropometrics and blood pressure were recorded for statistical analysis. 
 
The following anthropometric parameters were measured 
1) Body height, to the nearest 0.5 cm using a stadiometer with subjects in the erect position 
without shoes 
2) Body weight, using an electronic balance 
3) Waist circumference, to the nearest 0.5 cm using a 1 cm-wide measuring tape following the 
NHANES III protocol. The waist circumference was measured in standing subjects placing a 
measuring tape in a horizontal plane around the abdomen, half-way between the iliac crest and 
the rib edge on the mid right axillary line. Before reading the tape measure, the tape must be 
secure, but not too tight and parallel to the floor and the reading should be taken at the end of 
expiration.  
4) Systolic and Diastolic blood pressure, and heart rate, using a Mercury Sphygmomanometer 
(Riva-Rocci) from the non-dominant arm. The first and fifth Korotkoff sounds were taken to 
identify systolic and diastolic values respectively. Heart rate will be measured according to the 
palpatory method (30 seconds) after recoding the blood pressure. Blood pressure 
measurements were performed every 2 minutes by the same investigator until two 
measurements will differ no more than ±5 mm Hg for both systolic and diastolic value. The 
average of three measurements was considered for the study. 
 
Plasma/urine storage 
Plasma and urine samples will be stored in 200uL plasma aliquots and in 5ml urine aliquots respectively 
at – 80°C following standard procedure.  
 
4.3 Cardiovascular visit (V2) 
The cardiovascular visit will be performed at the Metabolic Diseases outpatient clinic of the 
Department of Internal Medicine and Biochemical Sciences (Parma University). Subjects will be 
required to be fasting and refraining from tea or caffeine intake since the previous day. Subjects will be 
asked not to take any medication before the visit but to carry medication with them to be taken after 
the visit is concluded. 
 
Carotid intima-medial thickness (IMT) 
A Doppler ultrasound carotid intima-medial thickness evaluation were performed in all subjects 
participating in the study. 
Measurement of the carotid intima-media thickness (IMT) is a non-invasive, ultrasound based test to 
quantify subclinical vascular disease which has been shown to be an independent predictor of 
myocardial infarction, stroke and death from coronary artery disease [90]. IMT assessment, together 
with carotid plaque evaluation, is a useful tool to redefine risk beyond traditional risk factors [91]. 
Subjects were examined in a supine position, comfortably position after removing clothing and jewelers 
in the area to be examined. 
A trained operator, blind to the patient general characteristics, performed all tests using a linear-phased 
multi-frequency (from 7 to 10 MHz) transducer on a HP SONOS 5500 ultrasound device. 
The examiner was seated at the patient’s head. An ultrasound-specific gel was applied on the neck to 
help the transducer making a secure contact with the skin. 
A continuous ECG registration was performed during the test and ultrasound image frames recorded 
on a digital support in the telediastolic phase of the cardiac cycle (deflection from the isoelectric line 
measured from the beginning of the QRS complex will be used as a reference), in order to avoid IMT 
variations related to carotid pulsatility. 
 
The imaging protocol involves obtaining three longitudinal sections with lateral, and anterior oblique 
views of the distal 10 mm of the right and left common carotid arteries, the carotid bifurcation, and the 
internal carotid artery.  
For each main carotid segment (common carotid arteries, the carotid bifurcation, and the internal 
carotid artery) longitudinal sections are recorded in loops of specific images in order to better visualize 
both the near and the far walls. 
For each projection, an electrocardiographic-triggered loop of at least 4 heart beats was recorded and 
subsequently analyzed by a single operator, using a semi-automated edge-detection and measurement 
system (Carotid Analyzer; Medical Imaging Applications LLC, Iowa, US). 
The maximum and average IMT was calculated performing measurements in 36 different points (2 
each side X 3 projections X 2 walls). 
The following figure shows the identification of near and far wall using a edge-detection software 
 
Figure 14: Snapshot of IMT identification during carotid ultrasound examination 
 
 
 
5 Gene expression profiling 
 
 
5.1 Peripheral blood mononuclear cells (PBMCs) isolation and 
processing 
 
Approximately 50 mL of peripheral blood was collected in fasting conditions from each volunteer in a 
BD Vacutainer tube containing EDTA as anticoagulant (Becton, Dickinson and Company, Franklin 
Lakes, NJ, US). PBMCs isolation was carried out in sterile condition under a laminar flow cabinet. 
Briefly, blood was aliquoted (10ml) and diluted 1:1 with Phosphate Saline Buffer (PBS), mixed by 
vortexing and centrifuged at 1400 rpm for 10 minutes. Serum supernatant containing platelets was 
removed leaving a 3-4 ml layer of leucocytes lying over a red blood cells pellet. A total of 5 ml of 
Lymphoprep (Amersham Pharmacia, UK) was added in each tube and samples were centrifuged at 
2200 rpm for 20 minutes at room temperature in order to isolate PBMCs following a centrifugation 
gradient. 
PBMCs (a layer between serum and Lymphoprep) were collected with a maxi pipette at the interface. 
Approximately 4 ml of PBMCs was obtained, of which 1ml was used for RNA extraction and the 
remaining 3ml were further processed to be stored in liquid nitrogen. The 3ml PBMC layer was diluted 
1:3 with HBSS (Hanks buffered saline solution with calcium and magnesium) (Sigma), samples were 
centrifuged at 1800 rpm for 10 minutes at 4 °C and each pellet was re-suspended in an equal volume of 
RPMI 1640 medium 20% Foetal Calf Serum (FCS). A RPMI 20% dimethyl sulfoxide (DMSO) solution 
was added drop by drop to the cell solution every 3-5 minutes. Cell suspension was aliquoted in 1ml 
criovials and placed at -80°C for 12 hours and subsequently placed in liquid nitrogen for final storage. 
 
 
5.2 RNA extraction and quality control 
 
One PBMC aliquot (1ml) was used for total RNA extraction for gene expression analysis. 
RNA extraction was performed using a commercial Kit (Qiagen RNeasy Mini kit) following 
manufacturer’s instructions92. Isolated RNA was also digested with RNase-Free DNase to remove 
possible DNA contamination. Samples were run onto 0.8% agarose RNase-free TAE agarose  gel 
containing 0.5ug/ml Ethidium Bromide in standard RNase free conditions to check for RNA quality 
(degradation or DNA contamination). RNA was then eluted with RNase-free water into a new 
microcentrifuge tube and stored at -80°C until hybridization. 
 
Extensive quality control testing of extracted RNA was done before hybridization to the array. 
Total RNA yield and absence of DNA contamination were checked using a NanoDrop ND-1000 UV-
Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA quality was assessed 
measuring the 28S/18S rRNA and the RNA Integrity Number (RIN) with a Bioanalyzer 2100, using 
RNA 6000 Nano Chips (Agilent Technologies, Santa Clara, CA, USA). 
The following picture shows the typical pherogram observed with Agilent’s Bioanalyzer for PBMC’s 
RNA. 
 
Figure 15: PBMC's RNA spectral analysis 
 
 
 
Assessing  the purity and the quality of extracted RNA is fundamental in a microarray experiment. 
The gold standard methods used in this field are the Nanodrop spectrophotometer and the Bioanalyzer 
2100. Nanodrop calculates the 260/280 and 260/230 adsorbance ratio, besides the RNA concentration. 
First ratio gives an estimation of protein contamination, and it must be included from 1.8 and 2. The 
second one reflect carbohydrates contamination, and it must be grater than 1.5. 
The following graph shows a low purity RNA that can’t be used for microarray experiment. A low 
quality RNA sample was discharged from further processing. 
 
Figure 16: Low purity RNA sample graph 
 
 
This graph shows a RNA sample with medium purity that has to be purified before experiment. This 
type of specimen quality was considered for hybridization only if the amount of extracted RNA allowed 
to perform an adequate purification process. 
 
Figure 17: Medium purity RNA sample graph 
 
 
The following graph shows the NanoDrop result for a good quality RNA sample. This type of sample 
was amplified, labeled and hybridized without further pre-processing. 
Figure 18: NanoDrop representation of good quality RNA sample 
 
 
Quality control was performed with Bioanalyzer 2100. This instrument gives as results 
electropherograms showing the degree of integrity of extracted RNA, with two distinct peaks 
representing the 18S and 28S ribosomal RNA and giving the RNA Integrity Number, that indicates the 
degree of integrity of RNA. 
 
1) Partially degraded RNA 
 
RIN=5.9 
 
2) Good quality RNA 
 After cRNA amplification and dye incorporation it is necessary to perform another control with 
Bioanalyzer. The resulting electropherogram should have a broad band. The majority of signal for 
amplified sample should fall into the size range from 200 to 2000 nucleotides. 
Red, Cy5 labeled cRNA; Blue, Cy3 labeled cRNA show the same size distribution.  
 
Figure 19: Distribution of a good RNA electropherogram after cRNA amplification 
 
 
 
 
5.3 Microarray hybridization and quality control 
 
As mentioned above the dual-color protocol allows a competitive hybridization among RNA sample 
and RNA reference, so that the RNA that expresses greater amounts of a given gene will competitively 
inhibit the hybridization of the other target. Thus at each coordinate on the slide, red or green 
fluorescence intensity is directly proportional to the amount of target present in one RNA sample 
compared to the other. 
A total of 500ng of total RNA for each sample (and each related reference) was reverse transcribed in 
cDNA in parallel with a given amount of spike-in RNA (Agilent Technologies, US) as internal control, 
followed by linear amplification and transcription in cRNA with the incorporation of a fixed 
proportion of nucleotides conjugated with fluorescent dyes. Reference RNA was labelled with green 
fluorescent molecule cyanine 3 (Cy3) while sample RNA was tagged by red fluorescent Cyanine-5 
(CY5). After labeling, conjugated-cRNA were purified through adsorbance columns (Qiagen, US) and 
re-tested for quality and integrity. Finally, sample and reference cRNA were mixed together in equal 
concentration and hybridizated together on 4X44 Whole Human Genome Agilent Microarray slides 
(Agilent Technologies, ref. G4112F). After 17 hours of incubation, slides were washed to discard 
unbounded cRNA and then scanned with an Agilent's G2565AA Microarray Scanner System. From the 
acquired high-resolution 16-bit tiff image, raw intensity data were extracted in numerical values using a 
dedicated software (Agilent's Feature Extraction, 9.5 V), which provides the values of log ratio of signal 
intensity. Dye-normalized, background-subtracted log-ratios of sample to reference expression were 
calculated.  
After scanning, row data are analyzed with the Feature Extraction software which gives as output the 
expression value and a quality report. This file shows if the array was hybridized correctly, if the signal 
intensity is consistent, and calculate the variability of probes replications. The simultaneous 
amplification of Spike In RNA is used as internal control. 
 
For further detail on the hybridization protocol, refer to the producer’s website [93] 
6  Statistical analysis 
 
To perform joint analysis of both clinical and gene expression data, different types of statistical 
approaches were used. This section describes the analysis plan, dividing the approach on the basis of 
the primary type of statistics used. Statistical approach to analyze clinical data will be described first, 
and then gene expression profile data handling will be discussed.  
The main aim of data analysis has been to verify the presence of associations between clinical factors 
(considered either continuously or after partition in classes) and gene expression data using the whole 
gene expression data set, without pre-filtering or data reduction strategies.  
Gene expression data were analyzed using two different levels of statistics: a first level statistic to allow 
the ranking of the expression values in relation to the clinical variable of interest, and then a second 
level statistic to provide results of enriched groups or pathways of genes accordingly to the rank. 
 
 
6.1 Clinical statistics 
 
Descriptive statistics 
Distributions of clinical parameters were tested for normality using Kolmogorov-Smirnov test. Non-
gaussian variables were rescaled to base 10 logarithm to produce normality. Descriptive statistics are 
reported in tables as mean ± SD, median and inter-quartile range (IQR), or count and percent, 
according to their distribution. 
 
Inferential statistics 
Between-group comparisons were performed on normal/ normalized variables using Student’s t-test 
and on non-continuous variables using Chi-square test. Presence of trends among more than two 
groups (i.e. LDL tertiles) was assessed using Analysis of Variance (ANOVA) test with linear polynomial 
contrast. 
The probability (p) value to reject null-hypothesis for clinical parameters was set at 0.05 with a two-tail 
distribution. No p-value correction for multiple comparisons was used for to compare clinical variables 
in order to ensure a high level of sensitivity.  
 Multivariate models for variable adjustment 
To identify a set of clinical predictors of a dependent clinical variable, Pearson’s correlation analysis was 
used. Clinical parameters correlated with the dependent variable with a p-value lower than 0.1 were 
considered as possible independent variables to be entrerd into the multivariate model. 
Multiple linear regression (MLR) analysis was performed to identify the independent predictors and 
estimate their relative impact. Age, gender, and all experimental measurements significantly associated 
with the dependent variable as described before, were entrered into the model as independent variables.  
In presence of several independent variables identified, analysis was performed with multi-step 
backward elimination (entry probability=0.05; removal= 0.15). Based on the final MLR model, values 
of the dependent variables were adjusted for the independet predictors in a subsequent MLR model. 
Fulfillment of the assumptions form MLR was checked by residual analysis and distribution/ 
correlation graphs. 
Statistical analysis for the clinical parameters was performed using software package SPSS 17.0 for 
Windows (SPSS Inc., Chicago, IL, US). 
 
 
6.2 Gene expression statistics 
 
Filtering and normalization of microarray data 
Probes with >50% missing values were excluded from the analysis.  Each experiment was standardized 
to have mean 0 and standard deviation of 1. Finally, probes annotated as targeting the same gene were 
combined by taking their median value of expression in each experiment.  
 
Differential expression  
One of the basic tasks in gene expression data analysis is finding differentially expressed genes between 
2 classes (such as tumor vs. normal or diabetics vs. non diabetics). A variety of methods were 
developed to address this task, such as TNoM (Ben-Dor et al., 2001A), SAM (Tusher et al., 2001) and 
others (see review of Cui and Churchill, 2003). In common practice bioinformaticians typically use 
categorical information on the samples to derive partitions. This study includes the investigation of the 
differential gene expression associated quantitative clinical phenotypes. We use two mechanisms for 
partitioning the set of samples (Supp Figure DA1): Parametric - Setting two values as thresholds (t and 
u) – all samples with phenotype value below t will be in class A, and all samples whose chosen 
phenotype value is above u will be in class B. The rest of the samples (between t and u) will be ignored. 
Non-parametric - Setting two percentile values as thresholds. Once the partition is determined one can 
use any measure of differential expression. In this study we used TNoM and Student t-test approaches. 
Differential expression in quantitative phenotypes is further discussed in 16.  
 
Enrichment analysis, mHG 
In our analyses we use methods to detect enrichment of a specific group of set at the top of a ranked 
list of genes. More formally, consider a universe gene set G = {gi}i=1..N , and a set of genes all 
participating in the same biological process, which we shall denote by T. Consider a candidate binary 
partition Q=(A, B) of the mRNA expression data and assume that for every transcript g  we computed 
a differential expression score, reflecting under/over expression in A as compared to B, denoted d(g). 
Rank the transcripts according to d(g), where the most significant transcripts are at the top of the list. 
We assign a statistical score to the enrichment of T at the top of this list. This enrichment score, 
e(Q,T,G), associates an activity of T with Q. e(Q,T,G) is computed using the mHG statistics (Eden et 
al., 2007 and 17). The enrichment procedure can be used with GO terms, TF cohorts, KEGG classes, 
miRNA target sets (as inferred from databases such as TARGETSCAN), genomic intervals and sets of 
genes derived from other studies. We use the same methods to statistically assess enrichment in lists 
ranked according to correlations, as is the case for the number of cigarettes smoked. 
 
7  Results 
 
At the end of the enrollment period, a total of 164 volunteers were identified and data collected. The 
final study population includes 91 males and 73 females, with a mean age of 37 years. Also in the 
overall population, enrolled subjects showed a low cardiovascular risk. The following table shows the 
characteristics of the enrolled population stratified by gender. 
 
Table 4: Clinical characteristics of the study overall population stratified by gender 
Variables 
Males 
(N=91) 
Females 
(N=73) 
Age [yy] * 37 ± 9 37 ± 7 
Smoking habit [current/former/never (%)]  (53.8/20.9/25.3) (71.2/11.0/17.8) 
BMI [kg/m2] 22,7 ± 3,3 25,8 ± 4,0 
Waist [cm] 83 ± 8 92 ± 11 
Systolic BP [mmHg] 109 ± 13 122 ± 14 
Diastolic BP [mmHg] 70 ± 13 80 ± 9 
Fasting plasma glucose [mg/dL] 84 ± 6 90 ± 10 
2-hour plasma glucose [mg/dL] 95 ± 23 94 ± 31 
Total-Cholesterol [mg/dL] 200 ± 29 205 ± 37 
HDL-Cholesterol [mg/dL] 67 ± 14 53 ± 13 
Triglycerides [mg/dL] * 54 (28) 73 (70) 
LDL-Cholesterol [mg/dL] 121 ± 27 134 ± 33 
WBC [Count*10^3/mm3] 5,863 ± 1,275 5,977 ± 1,374 
hsCRP [mg/L] * 0,74 (1,00) 0,65 (0,82) 
Footnote to the table: Continuous variables are expressed as mean ± SD or median (IQR), if not normally distributed 
(*); nominal variables (**) are presented as number (percent).  BMI = Body Mass Index, BP = Blood Pressure, HDL 
= High-Density Lipoprotein, LDL = Low-Density Lipoprotein, WBC = White Blood Cells, hsCRP = high 
sensitivity C-Reactive Protein. 
 As first analysis in the pivotal dataset, we explored the variability of gene expression profile as a 
function of the main demographic characteristics: gender, age and adiposity. 
 
 
7.1 Gender-specific gene expression profile 
 
Subjects were compared for expression values stratified by gender through differential expression 
analysis using TNoM scoring. As depicted in the following figure, we observed a substantially different 
expression profile between the two genders. Almost all the top 50 differentially expressed genes were 
involved in sexual differentiantion or were genes lying on the sexual chromosomes. 
 
Figure 20: Gene expression profile stratified by gender 
 
Footnote to figure. Heatmap of the 50 most differentially expressed genes between males and females. Each column 
corresponds to a patient and each row to a gene. Color represents log2 ratio of sample compared to reference. For 
illustration purposes, only genes with less than 25% of missing values have been represented. 
 
More in details, male subjects displayed –as predictable- the expression of genes located on the Y 
chromosome that are not present in females, whereas women showed a relevant over-expression of 
genes located on the X chromosome compared to men. The two following tables depicts the top 
differentially expressed genes between males and females. 
 
Figure 21: Most over-expressed genes in males compared to females 
 
 
Figure 22: Most over-expressed genes in females compared to males 
 
 
7.2 Age correlated gene expression profile 
 
To investigate whether age was associated with a specific expression profile, we performed a Pearson’s 
correlation analysis between age and gene expression values. As reported in the figure below, age 
resulted correlated with a specific gene expression profile. 
 
Figure 23: Gene expression profile associated with age 
 
Footnote to figure. Heatmap of the 50 genes most correlated with age. In the upper panel, the age value for each enrolled 
patient is displayed sorted on the x-axis for age value, from left to right. In the lower panel, each column corresponds to a 
patient and each row to a gene. Color represents log2 ratio of sample compared to reference. Each patient with his/ her 
age value reported in the upper panel corresponds to a column in the lower. For illustration purposes, only genes with less 
than 25% of missing values have been represented. 
 
The age of the subject resulted significantly and positively correlated with the expression of several 
groups of genes, based on GO analysis. More in detail, the assembly of chromosome and chromatin 
packaging resulted the most prominent signature over-expressed with increasing age. In addition, older 
age was associated with a pro-apoptotic signal and to a significant change in expression of groups of 
genes related to coagulation and fibrinolysis. However, the level of significance of this profile resulted 
relatively weak, with a p-value around 10-4. The only groups of genes that resulted significantly 
correlated with increasing age were related to chro
 Figure 24: Groups of genes significantly over-expressed with increasing age 
 
Footnote to figure. Figure shows the groups of genes significantly over-expressed by GO analysis. The panel depicts a 
graphical representation of the portion of the GO hierarchy that includes the terms significantly over-represented in the list 
of genes over-expressed in current smokers. Color is a function of the p-value of GO term enrichment by mHG analysis. 
 
 
7.3 Gene expression profile associated with white blood cell 
populations 
 
To verify whether the expression profile in circulating PBMCs could reflect the overall inflammatory 
state as determined by white blood cell sub-population count, we investigate the relationship between 
gene expression in PBMCs and the percentage of both neutrophiles and lymphomonocytes in the 
peripheral blood. Since gene expression microarrays are performed with a fixed starting amount of 
PBMC’s RNA, the presence of genes up- or down-regulated as a function of the relative concentration 
of leukocyte sub-populations appears to be dependent only upon the systemic environment determined 
by this proportion and not by the confounding presence of a different quantity of RNA from PBMCs. 
As shown in the following picture, a gene expression profile was identified both in relation to the 
relative concentration of neutrophiles and PBMCs. 
 
Figure 25: Gene expression profile associated with white blood cell sub-populations 
 
Footnote to figure. Heatmap of the 50 genes most correlated with leukocytes sub-populations. Each column corresponds to 
a patient and each row to a gene. The relative proprotion of the population is displayed sorted on the x-axis, increasing 
from left to right. Color represents log2 ratio of sample compared to reference. For illustration purposes, only genes with 
less than 25% of missing values have been represented. Panel A shows gene expression profile in relation to neutrophyle 
count, whereas panel B shows the gene expression profile assiciated with mononuclear cell cpount. 
 
As shown in the following picture, the presence of a relatively higher neutrophile count (in percentage 
of total white blood cells as well as in absolute count values) is associated with the over-expression of 
genes involved in the response to bacteric infections such as “response to bacterium” and “defense 
response to bacterium” (p-value of 4.5*10-7 and 1.3*10-6 respectively). In addition, genes more 
associated with the response to virus and parasites such as genes involved in the MHC class I and II 
defense mechanisms resulted down-regulated in subjects with relatively higher neutrophile 
concentraion [data not shown]. 
 
Figure 26: Groups of genes signficantly over-expressed in case of increasing neutrophile count 
 
Footnote to figure. Figure shows the groups of genes significantly over-expressed by GO analysis. The upper panel depicts 
a graphical representation of the portion of the GO hierarchy that includes the terms significantly over-represented in the 
list of genes over-expressed in current smokers. Color is a function of the p-value of GO term enrichment by mHG 
analysis and is coded following the scale depicted in the previous figures. Lower panel: GO terms significantly enriched in 
the list of genes over-expressed in current smokers. Enrichment is defined as (b/n) / (B/N), where N: total number of 
genes, B: total number of genes associated with a specific GO term, n: number of genes in the 'target set’, and b: number of 
genes in the 'target set' associated with a specific GO term. The reported p-values are not corrected for multiple testing. 
 
Conversely, the presence of relatively higher proportion of lymphomonocytes in the circuylating blood 
compared to neutrophiles, as assessed by leukocyte sub-population count, resulted associated with an 
increased expression of genes more associated to viral response and anatigen presentation, like MHC 
class I genes (following picture), whereas genes related to the response to bacterial infections resulted 
decreased [data not shown]. 
 
Figure 27: Groups of genes signficantly over-expressed in case of increasing lymphomonocyte 
count 
 
Footnote to figure. Figure shows the groups of genes significantly over-expressed by GO analysis. The upper panel depicts 
a graphical representation of the portion of the GO hierarchy that includes the terms significantly over-represented in the 
list of genes over-expressed in current smokers. Color is a function of the p-value of GO term enrichment by mHG 
analysis and is coded following the scale depicted in the previous figures. Lower panel: GO terms significantly enriched in 
the list of genes over-expressed in current smokers. Enrichment is defined as (b/n) / (B/N), where N: total number of 
genes, B: total number of genes associated with a specific GO term, n: number of genes in the 'target set’, and b: number of 
genes in the 'target set' associated with a specific GO term. The reported p-values are not corrected for multiple testing. 
 
 
7.4 Gene expression profile associated with emerging 
inflammatory markers 
 
The correlation analysis of gene expression profile with inflammatory cells and CVD risk factors 
illustrated so far support the hypothesis that expression profiling in circulating PBMCs is a suitable 
technique to identify the presence of the sub-clinical inflammation associated with CV disease. 
Currently, several candidate plasma markers are investigated with a similar approach. We therefore 
decided to investigate whether emerging inflammatory markers whose increase has been associated 
with CV risk are significantly correlated with apro-inflammatory gene expression profile in circulating 
PBMCs. To pursue this aim, we performed a Pearson correlation analysis of gene expression values 
with circulating levels of hsCRP and TNF-alpha. 
 
The following picture shows the results of the correlation analysis between hsCRP and gene expression 
in PBMCs. As it appears, higher hsCRP concentrations resulted associated with a significant increase in 
several group of genes, some of which related to some extent with leucocyte inflammatory response. 
However, the biological signal appears to be weak (maximum p-value level around 10-4) and without a 
strong internal consistency among gene groups. In addition, no specific KEGG pathway resulted 
significantly associated with hsCRP levels. 
 
Figure 28: Gene expression profile associated with plasma hsCRP concentrations 
 
Footnote to figure. Panel A shows the heatmap of the 50 genes most correlated with circulating hsCRP. Each column 
corresponds to a patient and each row to a gene. Color represents log2 ratio of sample compared to reference. For 
illustration purposes, only genes with less than 25% of missing values have been represented. Panel B shows a graphical 
representation of the portion of the GO hierarchy that includes the terms significantly over-represented in the list of genes 
over-expressed in correlation with hsCRP. Color is a function of the p-value of GO term enrichment by mHG analysis 
and is coded following the scale depicted in the previous figures.  
 
On the contrary, the circulating concentration of TNF-alpha resulted significantly associated with a 
gene expression profile characterized by a pro-inflammatory signature, as demonstrated by the 
significant over-expression of gene groups such as “Defense response” (p= 1.33*10-6), “Immune 
response” (p= 9.13*10-5), and “Complement activation” (p= 3.36*10-4) in subjects with relatively high 
TNF-alpha levels.The following picture shows the gene expression profile and the groups of genes 
significantly correlated with circulating TNF-alpha concentrations. 
 
Figure 29: Gene expression profile associated with circulating TNF-alpha concentrations 
 
Footnote to figure. Panel A shows the heatmap of the 50 genes most correlated with circulating TNF-alpha. Each 
column corresponds to a patient and each row to a gene. Color represents log2 ratio of sample compared to reference. For 
illustration purposes, only genes with less than 25% of missing values have been represented. Panel B shows a graphical 
representation of the portion of the GO hierarchy that includes the terms significantly over-represented in the list of genes 
over-expressed in correlation with TNF-alpha. Color is a function of the p-value of GO term enrichment by mHG 
analysis and is coded following the scale depicted in the previous figures. Panel C enlists in a tabular form the GO terms 
significantly enriched in the list of genes over-expressed in presence of higher TNF-alpha concentrations. Enrichment is 
defined as (b/n) / (B/N), where N: total number of genes, B: total number of genes associated with a specific GO term, 
n: number of genes in the 'target set’, and b: number of genes in the 'target set' associated with a specific GO term. The 
reported p-values are not corrected for multiple testing. 
 
 
7.5 Gene expression profile in relation to classical CVD risk 
factors 
 
As already detailed, we first conducted a proof-of-concept study on the first 50 enrolled patients to 
identify whether classical CVD risk factors that have already been associated with changes in gene 
expression profile in previous preliminary studies form other groups were correlated with relevant 
changes in gene expression also in our population. Out of the 50 patients enrolled, the RNA extracted 
from two PBMCs specimens resulted of insufficient quality to be hybridized, and were consequently 
excluded. A total of 48 patients were therefore included in this analysis. The presence of a correlation 
between gene expression and clinical characteristics of the population was checked using Pearson 
correlation analysis. The following clinical parameters were included into this bivariate exploratory 
analysis: smoking status, number of smoked cigarettes per week, LDL-cholesterol concentrations, 
systolic blood pressure, diastolic blood pressure, and fasting plasma glucose concentrations. Out of this 
analysis we identified relevant gene expression profiles in association with smoking status (and amount 
of cigarettes smoked) and LDL-cholesterol concentrations. 
 
7.5.1   General description of the pilot population  
As shown in the next table, the 48 selected volunteers included both males (N=20) and females (N=28), 
aged between 20 and 64 years (median 35, IQR 7). All subjects had a low cardiovascular risk as 
estimated by Framingham risk score[94], namely lower than 10% at 10 years. In addition, incidence of 
classical CVD risk factors in the cohort was fairly low: only 8 subjects had blood pressure above 
140/90 mmHg, none had impaired fasting glucose (as defined by fasting plasma glucose concentration 
of 100 mg/dL or more), and only 3 were glucose intolerant during OGTT (maximum 2-hour glucose 
value was 153 mg/dL). In addition, only 5 volunteers had LDL-cholesterol concentrations above 160 
mg/dL and only 8 were current cigarette smokers with a median weekly consumption of 65 cigarettes, 
whereas 28 had never smoked neither continuously nor occasionally. 
 
Table 5: Clinical characteristics of the pilot population stratified by gender 
Variables 
Males 
(N=20) 
Females 
(N=28) 
P 
Age [yy] * 34 (4) 36 (10) NS 
Smoking habit 
[never/former/current (%)] ** 
12/5/2 
(63.2/26.3/10.5) 
19/3/6 
(67.9/10.7/21.4) 
NS 
BMI [kg/m2] 25.5 ± 2.7 22.5 ± 3.0 0.001 
Waist [cm] 90 ± 9 82 ± 8 0.001 
Systolic BP [mmHg] 124 ± 11 106 ± 12 < 0.001 
Diastolic BP [mmHg] 82 ± 11 69 ± 10 < 0.001 
Fasting plasma glucose [mg/dL] 90 ± 5 85 ± 6 0.003 
2-hour plasma glucose [mg/dL] 100 ± 27 93 ± 20 NS 
Total-Cholesterol [mg/dL] 208 ± 43 199 ± 31 NS 
HDL-Cholesterol [mg/dL] 56 ± 15 71 ± 11 < 0.001 
Triglycerides [mg/dL] * 65 (120) 60 (35) NS 
LDL-Cholesterol [mg/dL] 130 ± 36 114 ± 31 0.036 
WBC [Count*10^3/mm3] 5.883 ± 0.997 6.009 ± 1.403 NS 
hsCRP [mg/L] * 0.65 (1.47) 0.67 (0.99) NS 
Footnote to the table: Continuous variables are expressed as mean ± SD or median (IQR), if not normally distributed 
(*); nominal variables (**) are presented as number (percent). Significance of difference between-groups has been evaluated 
using t-test or Chi-square (**) as appropriate. Not normally distributed variables (*) were log-transformed before t-test. 
BMI = Body Mass Index, BP = Blood Pressure, HDL = High-Density Lipoprotein, LDL = Low-Density 
Lipoprotein, WBC = White Blood Cells, hsCRP = high sensitivity C-Reactive Protein. 
 
7.5.2   Pro inflammatory expression profile in PBMCs in smokers  
The next table compares clinical variables between current smokers and subjects who never smoked. 
As it appears, the two groups did not differ in terms of age, gender distribution or cardiovascular risk 
factors, including inflammatory markers such as leukocyte count and hs-CRP. 
 
Table 6: Clinical characteristics of current smokers compared to non smokers 
Variables 
Never Smokers 
(N=31) 
Current Smokers 
(N=8) 
p 
Gender [M/F (%)] ** 12/19 (38.7/61.3) 2/6 (25.0/75.0) NS 
Age [yy] 35 ± 7 41 ± 10 NS 
Smoking habit [cigarettes/week] - 65 (63) - 
Smoking history [years] - 14.5 (11.0) - 
BMI [kg/m2] 23.1 ± 2.5 23.9 ± 4.9 NS 
Waist [cm] 84 ± 9 85 ± 11 NS 
Systolic BP [mmHg] 112 ± 13 110 ± 18 NS 
Diastolic BP [mmHg] 71 ± 17 73 ± 15 NS 
Fasting plasma glucose [mg/dL] 87 ± 5 87 ± 8 NS 
2-hour plasma glucose [mg/dL] 93 ± 24 86 ± 14 NS 
Total-Cholesterol [mg/dL] 195 ± 37 209 ± 29 NS 
HDL-Cholesterol [mg/dL] 65 ± 14 64 ± 13 NS 
Triglycerides [mg/dL] * 59 (39) 63 (25) NS 
LDL-Cholesterol [mg/dL] 115 ± 35 133 ± 26 NS 
WBC [Count*10^3/mm3] 5.81 ± 1.25 6.04 ± 1.92 NS 
hsCRP [mg/L] * 0.64 (0.71) 0.17 (1.34) NS 
Footnote to table: Continuous variables are expressed as mean ± SD or median (IQR), if not normally distributed (*); 
nominal variables (**) are represented as number (percent). Significance of between-group difference has been evaluated 
using t-test or Chi-square (**) as appropriate. Not normally distributed variables (*) were log-transformed before 
performing t-test. CAD = Coronary Artery Disease, CVD = Cardio-Vascular Diseases, BMI = Body Mass Index, 
BP = Blood Pressure, HDL = High-Density Lipoprotein, LDL = Low-Density Lipoprotein, WBC = White Blood 
Cells, hsCRP = high sensitivity C-Reactive Protein. 
 
Despite this similar clinical portrait, smokers showed a different gene expression profile, mainly 
characterized by a significant over-expression of genes related to generic GO terms of inflammation, 
like “immune system process” (p = 3.8 * 10-9), “immune response“ (p = 2.2 * 10-8) and “B cell 
activation” (p = 7.9 * 10-5), as shown in this figure. 
 
Figure 30: Gene expression profile in current cigarette smokers compared to subjects who have 
never smoked. 
A
B
C
SmokersNever smokers
 
Footnote to figure: Panel A: Heatmap of the 50 most differentially expressed genes between current and never smokers. 
Each column corresponds to a patient and each row to a gene. Color represents log2 ratio of sample compared to reference 
(see Methods). For illustration purposes, only genes with less than 25% of missing values have been represented. However, 
the full list of genes ranked according to their TNoM and t-test p-value (see methods) is available as supplementary 
material. Panel B: Graphical representation of the portion of the GO hierarchy that includes the terms significantly over-
represented in the list of genes over-expressed in current smokers. Color is a function of the p-value of GO term enrichment 
by mHG analysis and is coded following the scale depicted on top of the panel. Panel C: GO terms significantly enriched 
in the list of genes over-expressed in current smokers. Enrichment is defined as (b/n) / (B/N), where N: total number of 
genes, B: total number of genes associated with a specific GO term, n: number of genes in the 'target set’, and b: number of 
genes in the 'target set' associated with a specific GO term. The reported p-values are not corrected for multiple testing. 
 
Amongst the genes differentially expressed in smokers, we observed a significant up-regulation of 
several genes related to the response to interferon, like interferon alpha-inducible protein 6 (IFI6 
[NM_022873], TNoM p=0.0027) and interferon-induced protein with tetratricopeptide repeats 3 
(IFIT3 [NM_001549], TNoM p= 0.0027). In addition, smokers were also characterized by a significant 
over-expression of beta-chorionic gonadotropin (-hCG [NM_000737], TNoM p=0.0014), a marker 
of germ cell neoplasms95; sarcospan (SSPN [NM_005086], TNoM p= 0.0027), a gene inducing cell 
apoptosys in response to hypoxia96; and white blood cell-specific transcription factors such as the T-cell 
specific transcription factor 7-like 1 (TCF7L1 [NM_031283], TNoM p= 0.0030). The presence of an 
overall up-regulation of genes involved in the innate immunity in current smokers is also confirmed by 
a significant enrichment of several expression profiles previously observed in response to interferon 
and published in the Molecular Signatures Database [97] [data not shown]. 
To identify molecular pathways selectively enriched in current smokers, we searched the KEGG 
database and we observed a significant up-regulation (p<0.001) of several pathways associated with 
immune response and cancer (next table), as well as the down-regulation of the PPAR-g pathway (p= 
0.002). 
 
Table 7: Molecular pathways of the KEGG database enriched in genes over-expressed in current smokers 
compared to non-smokers 
Term 
Name 
Description P-value 
Enrichment 
(N, B, n, b) 
Genes 
04662 
B cell receptor 
signaling 
pathway 
9.22E-5 
9.12 
(15598,64,187,7) 
CD22 - cd22 molecule 
FCGR2B - fc fragment of igg, low affinity iib, 
receptor (cd32) 
RASGRP3 - ras guanyl releasing protein 3 (calcium 
and dag-regulated) 
BLNK - b-cell linker 
PIK3CD - phosphoinositide-3-kinase, catalytic, 
delta polypeptide 
CD79A - cd79a molecule, immunoglobulin-
associated alpha 
CD79B - cd79b molecule, immunoglobulin-
associated beta 
04080 
Neuroactive 
ligand-
receptor 
interaction 
1.01E-4 
2.62 
(15598,160,855,23) 
ADRA2C - adrenergic, alpha-2c-, receptor 
CNR1 - cannabinoid receptor 1 (brain) 
AGTRL1 - angiotensin ii receptor-like 1 
P2RX5 - purinergic receptor p2x, ligand-gated ion 
channel, 5 
HRH3 - histamine receptor h3 
TSHB - thyroid stimulating hormone, beta 
GABBR1 - gamma-aminobutyric acid (gaba) b 
receptor, 1 
NPY5R - neuropeptide y receptor y5 
PRSS1 - protease, serine, 1 (trypsin 1) 
GH1 - growth hormone 1 
GABRA1 - gamma-aminobutyric acid (gaba) a 
receptor, alpha 1 
P2RY6 - pyrimidinergic receptor p2y, g-protein 
coupled, 6 
TAAR8 - trace amine associated receptor 8 
GRM4 - glutamate receptor, metabotropic 4 
P2RY10 - purinergic receptor p2y, g-protein 
coupled, 10 
CYSLTR1 - cysteinyl leukotriene receptor 1 
PTGER1 - prostaglandin e receptor 1 (subtype 
ep1), 42kda 
NMUR2 - neuromedin u receptor 2 
OPRK1 - opioid receptor, kappa 1 
NPBWR2 - neuropeptides b/w receptor 2 
VIPR1 - vasoactive intestinal peptide receptor 1 
CRHR2 - corticotropin releasing hormone 
receptor 2 
CHRM1 - cholinergic receptor, muscarinic 1 
00602 
Glycosphingol
ipid 
biosynthesis - 
neo-lactoseries 
1.42E-3 
11.44 
(15598,19,287,4) 
tFUT4 - fucosyltransferase 4 (alpha (1,3) 
fucosyltransferase, myeloid-specific) 
FUT5 - fucosyltransferase 5 (alpha (1,3) 
fucosyltransferase) 
FUT6 - fucosyltransferase 6 (alpha (1,3) 
fucosyltransferase) 
GCNT2 - glucosaminyl (n-acetyl) transferase 2, i-
branching enzyme (i blood group) 
05213 
Endometrial 
cancer 
3.4E-3 
7.27 
(15598,49,219,5) 
TCF7L1 - transcription factor 7-like 1 (t-cell 
specific, hmg-box) 
PIK3CD - phosphoinositide-3-kinase, catalytic, 
delta polypeptide 
ARAF - v-raf murine sarcoma 3611 viral oncogene 
homolog 
TCF7 - transcription factor 7 (t-cell specific, hmg-
box) 
GRB2 - growth factor receptor-bound protein 2 
05221 
Acute myeloid 
leukemia 
4.12E-3 
4.68 
(15598,55,424,7) 
PIM2 - pim-2 oncogene 
TCF7L1 - transcription factor 7-like 1 (t-cell 
specific, hmg-box) 
PIK3CD - phosphoinositide-3-kinase, catalytic, 
delta polypeptide 
CCND1 - cyclin d1 
ARAF - v-raf murine sarcoma 3611 viral oncogene 
homolog 
TCF7 - transcription factor 7 (t-cell specific, hmg-
box) 
GRB2 - growth factor receptor-bound protein 2 
04620 
Toll-like 
receptor 
signaling 
pathway 
4.55E-3 
5.70 
(15598,85,193,6) 
MAP3K7IP1 - mitogen-activated protein kinase 
kinase kinase 7 interacting protein 1 
PIK3CD - phosphoinositide-3-kinase, catalytic, 
delta polypeptide 
FADD - fas (tnfrsf6)-associated via death domain 
CXCL10 - chemokine (c-x-c motif) ligand 10 
IRF7 - interferon regulatory factor 7 
Footnote: P-value' is the enrichment p-value computed according to the mHG or HG model. This p-value is not corrected 
for multiple testing. Enrichemnt (N, B, n, b) is defnied as follows: “N” is the total number of genes, “B” is the total 
number of genes associated with a specific term ('target' set and 'background set'), “n” is the number of genes in the 'target 
set', and “b” is the number of genes in the 'target set' associated with a specific term 
 
Among the pathways over-expressed in smokers, the most enriched (p = 9.22*10-5) resulted to be the 
“B-cell receptor signaling pathway”, a key step in innate response immunity and direct recognition of 
the antigen98, as well as in B cells selection and survival99. The next figure shows the “B-cell receptor 
signaling pathway” as represented in the KEGG encyclopedia. Genes shown in red appear to be 
upregulated in presence of smoking. 
 
Figure 31: Molecular pathway most over-expressed in current compared to never smokers by 
enrichment analysis on KEGG database: B-cell receptor signaling pathway. 
Enrichment = 9.12 (15598,64,187,7)
mHG p-value = 9.22*10-5
 
CD40 - cd40 molecule, tnf receptor superfamily 
member 5 
05215 
Prostate 
cancer 
6.2E-3 
6.67 
(15598,86,136,5) 
TCF7L1 - transcription factor 7-like 1 (t-cell 
specific, hmg-box) 
PIK3CD - phosphoinositide-3-kinase, catalytic, 
delta polypeptide 
TCF7 - transcription factor 7 (t-cell specific, hmg-
box) 
GRB2 - growth factor receptor-bound protein 2 
INS - insulin 
Footnote to figure: Graphical representation of the “B-cell receptor pathway” as provided in the KEGG database. Genes 
highlighted in red are over-expressed in smokers compared to non-smokers. Enrichment is defined by mHGM analysis as 
(b/n) / (B/N), where N: total number of genes, B: total number of genes included in a specific KEGG pathway, n: 
number of genes in the 'target set’, and b: number of genes in the 'target set' included in the specific KEGG pathway. 
 
In addition to this pathway, also the “Toll-like receptor signaling pathway” resulted over-expressed in 
smokers, further confirming an over-activation of mechanisms related to innate immunity (shown in 
the following graph). 
 
Figure 32: Molecular pathway most over-expressed in current compared to never smokers by 
enrichment analysis on KEGG database: Toll-like receptor signaling pathway 
 
Footnote to figure: Graphical representation of the “Toll-like receptor signaling pathway” as provided in the KEGG 
database. Genes highlighted in red are over-expressed in smokers compared to non-smokers. Enrichment is defined by 
mHGM analysis as (b/n) / (B/N), where N: total number of genes, B: total number of genes included in a specific 
KEGG pathway, n: number of genes in the 'target set’, and b: number of genes in the 'target set' included in the specific 
KEGG pathway. 
 
The pro-inflammatory signature found in smoker’s gene expression profile was also proportional to the 
level of smoking exposure, as assessed by Pearson’s correlation analysis of gene expression with weekly 
cigarette consumption. Next figure depicts the groups of genes that were significantly and positively 
correlated with cigarette consumption, assessed as number of cigarettes per week. Panel A shows the 
heatmap of the 50 most correlated genes (lower part of the panel) sorted on the x-axis in relation to 
number of smoked cigarettes (upper part of the panel). The enrichment of functional groups is very 
close to that observed in analyzing binary differential expression for smokers vs non-smokers (Panels B 
and C).  
 
Figure 33: Gene expression profile correlated with degree of exposure to cigarette smoking 
 
Footnote to figure. Panel A: Heatmap of the 50 genes most correlated with number of cigarettes smoked per-week. Each 
column corresponds to a patient and each row to a gene. Color represents log2 ratio of sample compared to reference (see 
Methods). For illustration purposes, only genes with less than 4 missing values have been represented. The full list of genes 
ranked according to correlation’s p-value is available as supplementary material. Panel B: Graphical representation of the 
portion of the GO hierarchy that includes the terms significantly over-represented in the list of genes directly correlated with 
degree of current smoking. Color is a function of the p-value of GO term enrichment by mHG analysis and is coded 
following the scale depicted on top of the panel. Panel C: GO terms significantly enriched in the list of genes directly 
correlated with degree of current smoking. Enrichment is defined as (b/n) / (B/N), where N: total number of genes, B: 
total number of genes associated with a specific GO term, n: number of genes in the 'target set’, and b: number of genes in 
the 'target set' associated with a specific GO term. The reported p-values are not corrected for multiple testing spanning 
5081 GO terms. 
 
In addition, the “Toll-like receptor signaling pathway” resulted the most enriched KEGG pathway 
amongst the genes positively correlated also with the degree of smoking (next figure). 
 
Figure 34: Molecular pathway most correlated with degree of exposure to cigarette smoking by 
enrichment analysis on KEGG database. 
Enrichment = 3.9*2(15598,85,656,14)
mHG p-value = 1.02*10-4
 
Footnote to figure. Graphical representation of the “Toll-like receptor pathway” as provided in the KEGG database. 
Genes highlighted in red are correlated with degree of exposure to cigarette smoking. Enrichment is defined by mHGM 
analysis as (b/n) / (B/N), where N: total number of genes, B: total number of genes included in a specific KEGG 
pathway, n: number of genes in the 'target set’, and b: number of genes in the 'target set' included in the specific KEGG 
pathway. 
 
 
7.5.3   High LDL-cholesterol is associated with a pro-inflammatory gene 
expression profile characterized by an over-expression of genes related to 
cell-mediated immune response 
The next table illustrates the clinical characteristics of the study population stratified by levels of LDL-
cholesterol: subjects of the third LDL tertile were characterized, in average, by moderately elevated 
LDL-cholesterol levels (157±18 mg/dL) and did not differ in any of the other clinical parameters from 
the individuals with lower LDL-cholesterol concentrations (1st and 2nd tertiles). Only hsCRP resulted 
slightly, but not significantly, elevated in the 3rd LDL-cholesterol tertile. 
 
Table 8: Clinical characteristics of the study population stratified by tertiles of LDL Cholesterol. 
LDL Cholesterol tertiles Trend 
Variables 1st 
(40-104 mg/dL) 
2nd 
(106-138 mg/dL) 
3rd 
(140-197 mg/dL) 
p 
Gender [M/F (%)] ** 5/10 (33.3/66.7) 6/10 (37.5/62.5) 9/7 (56.2/43.8) NS 
Age [yy] 34 ± 8 36 ± 7 37 ± 9 NS 
Family history of CAD 
[count (%)] ** 
2 (14) 1 (7) 2 (15) NS 
Family history of CVD 
[count (%)] ** 
3 (21) 3 (23) 3 (21) NS 
Smoking habit 
[current/former/never 
(%)] ** 
1/2/11 
(7.1/14.3/78.6) 
4/3/8 
(26.7/20.0/53.3) 
3/3/8 
(21.4/21.4/57.1) 
NS 
BMI [kg/m2] 24 ± 2 22 ± 3 25 ± 3 NS 
Waist [cm] 85 ± 7 81 ± 10 90 ± 8 NS 
Systolic BP [mmHg] 112 ± 16 110 ± 15 116 ± 13 NS 
Diastolic BP [mmHg] 66 ± 21 72 ± 13 76 ± 12 NS 
Fasting plasma glucose 
[mg/dL] 
85 ± 5 85 ± 6 91 ± 5 NS 
2-hour plasma glucose 
[mg/dL] 
87 ± 27 91 ± 17 100 ± 21 NS 
LDL Cholesterol tertiles Trend 
Variables 1st 
(40-104 mg/dL) 
2nd 
(106-138 mg/dL) 
3rd 
(140-197 mg/dL) 
p 
Total-Cholesterol 
[mg/dL] 
168 ± 25 203 ± 22 240 ± 24 NS 
HDL-Cholesterol 
[mg/dL] 
71 ± 14 65 ± 15 59 ± 14 NS 
Triglycerides [mg/dL] * 53 (32) 66 (40) 70 (132) NS 
WBC count [# * 
10^3/mm3] 
5.52 ± 0.82 6.24 ± 1.75 6.00 ± 1.11 NS 
hsCRP [mg/L] * 0.35 (0.72) 0.36 (0.85) 0.91 (2.00) NS 
Footnote to table: Continuous variables are expressed as mean ± SD or median (IQR), if not normally distributed (*); 
nominal variables (**) are represented as number (percent). Significance of trend among groups has been evaluated using 
analysis of variance (ANOVA) or Chi-square test (**) as appropriate. Not normally distributed variables (*) were log-
transformed before performing ANOVA test. CAD = Coronary Artery Disease, CVD = Cardio-Vascular Diseases, 
BMI = Body Mass Index, BP = Blood Pressure, HDL = High-Density Lipoprotein, LDL = Low-Density 
Lipoprotein, WBC = White Blood Cells, hsCRP = high sensitivity C-Reactive Protein. 
 
However, we detected a significant association between the expression level of many genes and the 
individual’s LDL-cholesterol concentration. To better characterize the genes that were differentially 
expressed in high compared to low LDL-cholesterol concentrations, we compared LDL≤ 104 to 
LDL≥ 140  mg/dL, the extreme tertiles of the cohort distribution. 
As shown in the next figure, the gene expression signature associated with high LDL-cholesterol was 
characterized by an over-representation of genes involved in the inflammatory response, with a 
preferential enrichment of GO terms associated with the cell-mediated immunity such as “antigen 
processing and presentation via MHC class II” (p = 8.0*10-7). 
 
Figure 35: Gene expression profile in subjects with high (> 140 mg/dL) compared to low (< 
104 mg/dL) plasma LDL-cholesterol concentrations. 
A
B
C
 
Footnote to figure. Heatmap of the 50 most differentially expressed genes between high and low LDL-cholesterol 
concentrations determined by semi-supervised class discovery. Each column corresponds to a patient and each row to a gene. 
Color represents log2 ratio of sample compared to reference. For illustration purposes, only genes with less than 4 missing 
values have been represented. Panel B: Graphical representation of the portion of the GO hierarchy that includes the terms 
significantly over-represented in the list of genes over-expressed in high LDL. Color is a function of the p-value of GO 
term enrichment by mHG analysis and is coded following the scale depicted on top of the panel. Panel C: GO terms 
significantly enriched in the list of genes over-expressed in high LDL. Enrichment is defined as (b/n) / (B/N), where 
N: total number of genes, B: total number of genes associated with a specific GO term, n: number of genes in the 'target 
set’, and b: number of genes in the 'target set' associated with a specific GO term. The reported p-values are not corrected 
for multiple testing. 
 
In addition, the most enriched cellular pathway in presence of high LDL-cholesterol resulted to be the 
antigen processing and presentation through the MHC class II pathway (p = 1.8*10-4) whose key genes 
were all significantly up-regulated (next figure). 
 
Figure 36: Molecular pathway most over-expressed in high (> 140 mg/dL) compared to low (< 
104 mg/dL) LDL-cholesterol by enrichment analysis on KEGG database. 
Enrichment = 4.63 (15598,71,474,10)
mHG p-value = 4.19*10-4
 
Footnote to figure. Graphical representation of the “Antigen processing and presentation pathway” as provided in the 
KEGG database. Genes highlighted in red are over-expressed in subjects with high LDL-cholesterol concentrations. 
Enrichment is defined by mHGM analysis as (b/n) / (B/N), where N: total number of genes, B: total number of genes 
included in a specific KEGG pathway, n: number of genes in the 'target set’, and b: number of genes in the 'target set' 
included in the specific KEGG pathway. 
 
 
7.5.4   Cigarette smoking and high LDL-cholesterol activate both innate as 
well as cell-mediated immune response 
In the previous sections, we described the response of PBMCs to cigarette smoking and to high LDL-
cholesterol, in terms of changes in mRNA expression levels. Exposure to smoking leads to an 
activation of the innate immune response system while high plasma LDL-cholesterol concentrations 
are associated with an activation of the cell-mediated immune response pathways. It is therefore likely 
that different risk factors act through distinct pathophysiological mechanisms and the pathogenesis of 
atherosclerosis might be driven by each factor in a distinct manner. To test the effect of the presence of 
both factors in the same individual we compared the PBMC expression profiles of current smokers 
with high LDL-cholesterol concentration to that of never smokers with low plasma LDL-cholesterol. 
As depicted in the following figure, we observed a strong enrichment of gene sets related to both types 
of immune response, including general innate inflammatory response (Response to stimulus with p~10-
4 ) as well as cell-mediated immunity. The latter is exemplified by the GO term including genes involved 
in antigen presentation through the HMC class II pathway, which contains 17 members in the entire 
human genome, 10 of which appeared significantly differentially expressed in our comparison. The 
latter enrichment yields a p-value of 1.08*10-6. 
 
Figure 37: Gene expression profile in current cigarette smokers with high plasma LDL-
cholesterol concentrations compared to non-smokers with low LDL-cholesterol. 
AB
C
 
Footnote to figure. Panel A: Heatmap of the 50 most differentially expressed genes between current smokers with high 
LDL-cholesterol and never smokers with low LDL-cholesterol. Each column corresponds to a patient and each row to a 
gene. Color represents log2 ratio of sample compared to reference (see methods) and legend scale is depicted above the 
heatmap. For illustration purposes, only genes with less than 25% of missing values have been represented. Panel B: 
Graphical representation of the portion of GO tree including the terms significantly over-represented in the list of genes 
over-expressed in current smokers with high LDL-cholesterol concentrations. Color is a function of the p-value of GO 
term enrichment by mHG analysis and is coded following the scale depicted on top of the panel. Panel C: GO terms 
significantly enriched in the list of genes over-expressed in current smokers with high LDL-cholesterol concentrations. 
Enrichment is defined as (b/n) / (B/N), where N: total number of genes, B: total number of genes associated with a 
specific GO term, n: number of genes in the 'target set’, and b: number of genes in the 'target set' associated with a specific 
GO term. 
 
7.5.5   RT-PCR validation 
Out of the list of genes over-expressed in smokers with high plasma LDL-cholesterol concentrations 
and ranked according to TNoM and t-test p-value, we identified 7 highly meaningful candidate genes 
representing both innate and cell-mediated immunity, including chemokine (CXCL10), interferon (IFI6 
and STAT2) and TNF (CD40) related genes, HLA class II histocompatibility (CD74) and immune cell 
activation/ proliferation (CD20). 
As shown in the following figure, the expression profile of the validation genes resulted significantly 
higher in smokers with high LDL compared to non smoker with low LDL concentrations. The 
expression pattern in each subject appeared to be similar when assayed by microarray and traditional 
RT-PCR evaluation as shown by head-to-head comparison of heatmaps.  
 
Figure 38: Expression profile of the seven validation genes assessed by microarray and RT-
PCR essay. 
 
Foonote to figure. Table lists annotation data of the seven validation genes and p-value for Student’s T-test comparison 
between smokers with high plasma LDL-cholesterol concentrations and non-smokers with low LDL-cholesterol. Figure 
shows the heatmap of expression profile of the seven validation genes assessed by microarray (top-panel) and RT-PCR 
essay (bottom panel). Color represents log2 ratio of sample compared to reference for microarray data and arbitrary units 
for RT-PCR. 
 
 
7.6 Gene expression profile in relation to carotid intima-media 
thickness 
 
Although ours as well as other group’s data have been showing the presence of a significant correlation 
between CV risk factors and certain gene expression profiles, commonly characterized by a pro-
inflammatory signature, no data so far have emerged investigating whether the gene expression profile 
is correlated with the extent and severity of atherosclerotic vascular damage, also in a pre-clinical stage. 
To pursue this aim, we investigate the relationship between gene expression profile and carotid IMT 
values in our population of apparently ehalty young adults. The following table shows the 
characteristics of our study population when stratified by quartiles of IMT value. As it is appears, also 
the subjects in top IMT quartile showed relatively normal IMT values, in most of the cases below 1 mm. 
Despite this substantially normal carotid IMT profile, subjects in the fourth quartile showed a 
significantly higher CV risk profile characterized by a prevalent proportion of males over females, a 
greater age and adiposity (both BMI and waist circumference), and higher plasma glucose and LDL-
cholesterol concentrations. 
 
Table 9: Clinical characteristics of the study overall population stratified by IMT values 
IMT quartile  
Linear contrast 
ANOVA 
Variable 
1st 
0.60-0.74 
mm 
2nd 
0.75-0.80 
mm 
3rd 
0.81-0.88 
mm 
4th 
0.90-1.06 
mm 
 F P 
Gender [M(%)] 11 (35.5) 18 (48.6) 30 (76.9) 21 (58.3)  - ,004 
Age [yy] 33 ± 6 36 ± 8 37 ± 7 42 ± 9  7,892 ,000 
BMI [kg/m2] 23.6 ± 2.8 23.2 ± 3.3 25.3 ± 3.6 25.9 ± 5.6  3,846 ,011 
Waist [cm] 86 ± 8 85 ± 9 90 ± 11 93 ± 13  4,264 ,006 
SBP [mmHg] 114 ± 11 115 ± 14 116 ± 16 122 ± 17  1,988 NS 
DBP [mmHg] 72 ± 16 75 ± 9 77 ± 12 77 ± 10  1,067 NS 
FPG [mg/dL] 85 ± 5 86 ± 6 88 ± 6 91 ± 14  4,139 ,008 
IMT quartile  
Linear contrast 
ANOVA 
Variable 
1st 
0.60-0.74 
mm 
2nd 
0.75-0.80 
mm 
3rd 
0.81-0.88 
mm 
4th 
0.90-1.06 
mm 
 F P 
2h PG [mg/dL] 99 ± 26 90 ± 20 88 ± 20 102 ± 39  2,242 ,086 
Tot Chol [mg/dL] 199 ± 35 202 ± 34 196 ± 30 216 ± 31  2,857 ,039 
HDL Chol [mg/dL] 62 ± 17 64 ± 15 56 ± 13 59 ± 14  1,784 NS 
TG [mg/dL] 58 (75) 58 (38) 72 (34) 58 (34)  ,916 NS 
LDL Chol [mg/dL] 119 ± 32 125 ± 31 125 ± 29 142 ± 27  3,721 ,013 
hsCRP [mg/dL] 0.75 (0.81) 0.50 (0.55) 0.63 (0.93) 1.04 (1.89)  1,297 NS 
Smokers [N(%)] 6 (18.8) 6 (18.8) 12 (36.4) 9 (27.3)  - NS 
Footnote to the table: Continuous variables are expressed as mean ± SD or median (IQR), if not normally distributed 
(*); nominal variables (**) are presented as number (percent).  BMI = Body Mass Index, BP = Blood Pressure, HDL 
= High-Density Lipoprotein, LDL = Low-Density Lipoprotein, WBC = White Blood Cells, hsCRP = high 
sensitivity C-Reactive Protein. 
 
In addition to these findings, IMT values were significantly correlated with a PBMC transcriptomic 
profile characterized by increased expression of groups of genes involved in cell cycle and mitosis (GO 
terms: “Cell division” p=1.1E-9; “Cell cycle phase” p=6.7E-9; “Cell cycle process” p=1.5E-8;”Mitosis” 
p=3.3E-7; etc.) and mithocondrial oxidative phosphorylation (“electron transport” p=5.5E-6; 
“mitochondrial electron transport” p=5.4E-5),as shown in the following figure. 
 
 
Figure 39: Groups of genes significantly correlated with IMT values 
 
Footnote to figure. Panel A shows a graphical representation of the portion of the GO hierarchy that includes the terms 
significantly over-represented in the list of genes over-expressed in correlation with carotid IMT values. Panel B enlists in a 
tabular form the GO terms significantly enriched in the list of genes over-expressed in presence of higher TNF-alpha 
concentrations.  
 
Consistently with these findings, the “oxidative phosphorylation” pathway resulted as the most 
significantly up-regulated KEGG pathway in presence of high IMT (p=1.8E-8), followed by the cell 
cycle pathway (p=3.6E-5).  
The genes significantly up-regulated in relation with IMT values of the two pathways are depicted in 
red in the following figure. 
 
Figure 40: Molecular pathways significantly over-expressed in presence of higher IMT values 
 
Footnote to figure: Graphical representation of the two molecular pathways most correalted with IMT values as provided 
in the KEGG database. Genes highlighted in red are over-expressed in smokers compared to non-smokers. Enrichment is 
defined by mHGM analysis as (b/n) / (B/N), where N: total number of genes, B: total number of genes included in a 
specific KEGG pathway, n: number of genes in the 'target set’, and b: number of genes in the 'target set' included in the 
specific KEGG pathway. 
 
Although this profile resulted consistent in both types of analysis (GO and KEGG enrichment 
analysis) and significantly associated with IMT values, it was not possible from a bivariate approach to 
exclude the possible presence of confounders, as IMT resulted associated with several clinical 
characteristics and CVD risk factors. 
As shown by table 4, IMT resulted increate in subjects of male gender, and higher age, BMI, waist 
circumference, plasma glucose and LDL-cholesterol concentrations. To adjust IMT values for the 
presence of confounders, we performed a multivariate linear regression analysis, including gender, age, 
BMI, plasma glucose and LDL-cholesterol as independent variables. Out of these variables, only age 
resulted independently correlated with IMT values (next table). 
 
Table 10: IMT predictors by linear regression analysis 
Variabile Beta p R2 
Sesso 0.112 N.S. 
Età 0.440 <0.001 
BMI -0.021 N.S. 
Glicemia a digiuno 0.070 N.S. 
Glicemia post-carico -0.070 N.S. 
LDL colesterolo 0.021 N.S. 
0,187 
 
We therefore adjusted IMT values by age using linear regression analysis. After age-adjustment, IMT 
values resulted significantly correlated with the same gene groups and pathways with a higher level of 
significance. An increase in transcription of oxidative phosphorylation genes resulted the bio-signal 
most strongly correlated with age-adjusted IMT values (p=6.4E-12), as shown in the following figure. 
The value of the significance of the association resulted even increased after age-adjustment. 
 
Figure 41: Groups of genes significantly correlated with IMT values after age-adjustment 
 
Footnote to figure. Panel A shows a graphical representation of the portion of the GO hierarchy that includes the terms 
significantly over-represented in the list of genes over-expressed in correlation with carotid IMT values. Color is a function 
of the p-value of GO term enrichment by mHG analysis and is coded following the scale depicted in the figure. Panel B 
enlists in a tabular form the GO terms significantly enriched in the list of genes over-expressed in presence of higher TNF-
alpha concentrations. Enrichment is defined as (b/n) / (B/N), where N: total number of genes, B: total number of genes 
associated with a specific GO term, n: number of genes in the 'target set’, and b: number of genes in the 'target set' 
associated with a specific GO term. The reported p-values are not corrected for multiple testing. 
Figure 42: Molecular pathways significantly over-expressed in presence of higher IMT values 
after age-adjustment 
 
Footnote to figure: Graphical representation of the two molecular pathways most correalted with IMT values as provided 
in the KEGG database. Genes highlighted in red are over-expressed in smokers compared to non-smokers. Enrichment is 
defined by mHGM analysis as (b/n) / (B/N), where N: total number of genes, B: total number of genes included in a 
specific KEGG pathway, n: number of genes in the 'target set’, and b: number of genes in the 'target set' included in the 
specific KEGG pathway. 
 
 
8   Discussion 
 
White blood cells, especially lympho-monocytes, are high involved in the genesis and progression of 
atherosclerosis. Despite this well known paradigma, only a very limited experience has been made 
trying to identify disese biomarkers directly related to the phenotype of these cells. In the current set of 
studies we provide exploratory data (both from an initial pilot dataset and a pivotal, larger population) 
that consistenlty show the presence of pro-inflammatory signatures in gene expression profiles of 
circulating PBMCs in presence of exposure to CVD risk factors in volunteers of young-adult age, 
without evident clinical diseases and characterized by a low CVD risk profile. 
These data provide for the first time a coherent framework that can be used as exploratory finding to 
build further gene expression signature profiling study for the identification of potential biomarkers of 
CVD risk. 
In our population, gene expression profile of PBMCs varies significantly according to several 
parameters, including gender and age.  
To verify whether PBMCs expression profile could provide intelligible information on inflammatory 
processes, we verified how the transcriptome of these cells could be influenced by the WBC 
environment itself. We therefore investigated the correlation between gene expression profile and WBC 
population composition. As already mentioned in the results, the amount of RNA hybridized on the 
array is constant and therefore not influenced by the presence of a greater or smaller PBMC count. 
What influences the profile is the cytokine environment to which the PBMCs are exposed, which is on 
the contrary high dependent upon the relative proportion of circulating PBMCs over the other WBC 
components, especially neutrophiles. In presence of a relative imbalance toward neutrophiles, which are 
mainly deputed to the defense against bacterial infections, PBMC expression profile was indeed 
characterized by an over-expression of genes associated to the immune response to bacteria. 
Conversely, the relative abundance of PBMCs was associated with an over-expression of genes 
involved in MCH calls are response, which is the typical cellular response to viral exposure. In both 
cases, the down-regulation of the opposite signature pattern was also present, further supporting the 
capacity of this approach to grasp subtle biological differences. 
 
In presence of well known CVD risk factors, such as LDL-cholesterol and smoking, PBMCs 
consistently show a pro-inflammatory profile, observed both at the level of groups of transcripts 
differentially regulated and over-represented molecular pathways. 
Even more interestingly, different CVD risk factors appear to be associated to different gene 
expression profiles, although all in the direction of bursting the inflammatory response. Indeed, we 
observed that exposure to cigarette smoking produces a significant over-expression of genes involved 
in the innate immunity and the first stages of the inflammatory process. This type of immunity is more 
implicated than cellular-mediated immunity in responding to chemical stimuli. On the contrary, the 
presence of significantly higher (although close to the range of clinical normality) concentrations of 
LDL-cholesterol appears to be associated to a different pro-inflammatory profile, closer to the cellular-
mediated immunitary response. Although it could be argued that there are random and assay-related 
factors of variability that can differentiate the two profiles without the existence of a true biological 
difference, the statistical signal behind these two profiles appears to be sufficiently strong and 
consistent independently of the second level analysis used. In addition to the analyses here reported, we 
also compared the two expression profiles with the expression profiles collected in the Molecular 
Signature database (MSig). A search for similar profiles in the database, identified several different 
molecular signatures characteristics of the exposure of in-vitro cells to chemical agents or generic 
stimuli such as toxins in the first case, and the response to bacteria or cytokines of the cellular mediated 
response in the latter. 
Finally, the co-presence of exposure to both CVD risk factors was characterized by an additive effect 
on gene expression where characteristics of both profiles were identifiable. 
It is of interest to highlight that this striking molecular signature was observed in subjects who –for the 
same sample size- did not show any clinically meaningful difference in CVD risk factors. Besides, also 
hs-CRP resulted perfectly overlapping in values between the two groups, although it is widely 
considered a bio-marker of the low-grade inflammation induced by CVD risk factors. 
Also in this case, gene expression profile appeared consistent with this finding when the transcriptome 
of PBMCs was correlated with circulating hs-CRP concentrations. Hs-CRP in fact resulted not 
associated with a specific gene expression profile, representative of CVD –related inflammation. On 
the other hand, a pro-inflamamtory profile was instead observed in correlation with circulating levels of 
other cytokines, like TNF-alpha and IL6 [not shown]. 
 
Although some preliminary data of correlation between gene expression in circulating cells and CVD 
risk factors are already available in the literature, no study tried to verify whether the presence of 
vascular damage (even at a early stage) was associated with a specific expression profile. From this point 
of view, it should be noted that several CVD biomarkers such as hs-CRP are only poorly associated 
with vascular markers of the atherosclerotic burden, like carotid IMT and vascular Flow-Mediated 
Dilation (FMD). 
In a bivariate analysis we observed that a higher IMT (although within the boundaries of normality) was 
associated with a specific gene expression profile. The same profile was observed (even more strongly) 
after adjustment for relevant clinical confounders by a multivariate model. In addition, in a secondary 
analysis, the random sampling of less than 50% of the total sample showed, in correlation analysis with 
IMT, a similar result with similar level of statistical significance [data not shown], thus showing a 
relevant consistency of the biological signal 
The profile associated with high IMT appears to be characterized by a dramatic over-expression of 
genes involved in the cell cycle and in the mitochondrial respiratory chain. Taken as such these data 
appear difficult to be put into a clear clinical or patho-physiological perspective. Both of these 
signatures can be considered typical of activated cells that are moving toward self-replication and 
activation. Even sticking to this conservative explanation, it is clear that the fact that inflammatory cells 
of an healthy individual are consistently and highly activated in concordance with the presence of a sign 
of vascular organ damage it is of high interest. In addition, increased expression of respiratory chain 
proteins are also a typical feature of cells with pro-oxidant unbalance of the redox system. The increase 
in generation of oxidative stress is indeed a cornerstone of CVD inflammation. 
Unfortunately the descriptive nature of cross-sectional studies and array profiling do not allow to 
further speculate over this intense statistical signal. Further experiments are therefore needed to 
establish the direction of these changes and their impact on cellular phenotype. 
However, it appears consistent that the expression profile of circulating PBMCs of subjects exposed –
in a relatively limited extent- to CVD risk factors are collectively characterized by pro-inflammatory 
features. This inflammatory signature appears, in our preliminary experience, to be different in presence 
of different CVD risk factors. Although this dataset is not sufficient to confirm whether this features 
are universally identifiable and whether different risk factors can trigger different cellular responses, it 
provides a pilotal data framework that support the interest for further investigations in this area of 
research. 
 
The present data have been collected using a high-throughput technique for gene expression profiling 
called microarray. Microarrays become possible after the extensive search of the genome project that 
provided sufficient meta-data for almost all the human transcripts. Microarrays are complex not in 
terms of laboratory execution, but foremost in terms of interpretation. Several of the common 
statistical rules do not apply in presence of huge amount of data of skewed and inconsistent 
distribution. A typical analysis of microarray data is devoted to decrease data dimensionality, usually 
comparing gene-by-gene the expression in two different groups of samples. The p-value of the 
comparison (or any other figure of merit) is then used to isolate a group of differentially expressed 
genes using more or less arbitrary thresholds. The list of selected genes is then usually explored gene-
by-gene searching for biologically interesting genes. This approach is prone to selection bias, since we 
are naturally more interested in interesting genes than in unknown or apparently unrelated trascript 
extracting selectively nicer (but less informative) results. 
The analysis techniques applied in this set of study is one of the strongest points of the project, as they 
preserve all the unique characteristics of microarray (for instance the fact of using always all the 
measured genes to extract results) and provide a more objective way of classifying the biological 
relevance of results. 
In brief, all bivariate analyses have been performed using correlation analysis or non-parametric 
comparisons to ensure a reliable proportion of significance among different genes. The list of all 
assayed genes has then been resorted based on p-value as figure of merit of the correlation/ 
comparison. No direct analysis of the bivariate list of genes has been provided in order to avoid 
identification bias. The overall gene set has been therefore tested for presence of enrichment of all the 
known groups of genes classified in the GO DAVID database. The list of genes was searched to 
identify the relative position in the ranking of each gene of each GO group. Then the distribution of 
the relative ranking of all genes in each GO term has been tested against what expected by random 
allocation. In presence of an high prevalence of genes at higher or lower end of the ranking spectrum in 
one GO group, more than what significantly plausible by chance, the group has been considered 
significantly over-enriched and a p-value has been assigned. The same type of analysis was conducted 
on the molecular pathways stored in the KEGG database. The two databases are completely 
independent and representative of different type of gene associations. Therefore the consistency of 
results between the two is a valuable indicator of the presence of a true biological signature. 
 
On the other hand, the study is prone –by design- to several weaknesses: first, it is cross-sectional and 
therefore no causality can be assessed between the clinical phenotypes and the gene signatures 
identified; then, the relatively small sample size does not allow to identify more subtle differences 
between signatures or signatures of other clinical parameters; third, a second, independent population is 
needed to confirm all the findings. 
These limitations are implicit in the exploratory nature of the project. Said that, it should on the other 
hand noted that several signs of internal consistency are present, as reviewed in this discussion section. 
Therefore, this study can be considered the first structured dataset suggesting that the exposure to 
CVD risk factors is associated to a significant change in gene expression profile of circulating PBMCs, 
which appear to switch over a pro-inflammatory phenotype. This phenomenon is perfectly in line with 
the inflammatory hypothesis of atherogenesis and provides further insights into the very early steps of 
the bursting of the inflammatory response that accompanies CVD origin and progression. The further 
definition of these pro-inflammatory signatures is of high relevance, as they can constitute significant 
biomarkers of biological response to CVD risk exposure, helping to identify which subjects are 
responding to a pro-atherogenic environment in the least adaptative way: with disease progression. 
Pivotal confirmation of these findings, exploration of the effect of exposure to treatment and cohort 
follow-up of these signatures appear to be the necessary steps to be taken in order to procede in the 
direction of candidate discovery for pro-atherogenic PBMC inflammation. 
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